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COMPOUNDS INCLUDING COX INHIBITOR 
MOIETY AND ENHANCED DELIVERY OF 
ACTIVE DRUGS USING SAME 
RELATED APPLICATIONS 
This application claims priority from U.S. Provisional 
Application Ser. No. 61/517,874 filed Apr. 27, 2011, the 
entire disclosure of which is incorporated herein by this 
reference. 
GOVERNMENT INTEREST 
2 
2003, the number of prescriptions for two buprenorphine 
formulations for the treatment of opioid dependence 
increased from 48,000 ($5 million) to 1.9 million ($327 
million) in 2007 (Mark, 2009). Unfortunately, the buprenor-
5 phine sublingual tablets have a very bitter taste and potential 
for "peak" plasma drug level related side effects (dizziness, 
sedation, orthostatic hypotension), and the poor acceptance 
of the drug has limited the use. 
Alcohol use disorders (AUDs) are a major public health 
10 problem (Breese et al., 2005; Koob and Le Moal, 2005; 
Sinha, 2007), and alcohol abuse is one of the leading causes 
of death in the United States, contributing to over 80,000 
deaths annually (Mokdad et al., 2004). Alcohol consumption 
This invention was made with govermnent support under 
NIH R01DA13425 awarded by the National Institutes of 15 
Health. The govermnent has certain rights in the invention. 
accounts for 9% of the disease burden in developed coun-
tries and is linked to more than 60 diseases including 
cancers, cardiovascular diseases, liver cirrhosis, neuropsy-
chiatric disorders, injuries and fetal alcohol syndrome (Cass-
well and Thamarangsi, 2009; Schuckit, 2009; WHO, 2004). 
Prescriptions for alcoholism increased from 393,000 ($30 
TECHNICAL FIELD 
The presently-disclosed subject matter relates to com-
pounds including a cyclooxygenase enzyme inhibitor moi-
ety. In some embodiments, the compound includes a Cox 
inhibitor moiety and an opioid. The compounds allow for 
improved microneedle-enhanced delivery rates across skin, 
as well as an increase in the pore lifetime or duration of 
delivery. 
INTRODUCTION 
According to the National Survey of Drug Use and Health 
(NSDUH) of 2008, 7 .2 million Americans are in need of 
treatment for Substance-Related Disorders (SRDs), and a 
large proportion of those need treatment for opiate pain 
reliever and heroin addiction. Additionally, over 8.5% of the 
U.S. population and 75 million people worldwide meet the 
diagnostic criteria for alcohol use disorders (AUDs), with 
alcohol abuse being among the top three preventable public 
health problems in the U.S. and the world. 
Opioid and alcohol abuse are major worldwide problems 
connected with tremendous social and personal strife. The 
CDC reported in February 2011 that the abuse of and deaths 
from prescription opioid narcotics has reached epidemic 
levels. In May 2009 the Columbia University National 
Center on Addiction and Substance Abuse reported that 
$468 billion dollars were spent by the Govermnent in 2005 
on expenses related to smoking, alcohol abuse, and illegal 
drugs. Prevention, treatment and addiction research spend-
ing comprised only about 2% of that $468 billion. Taxpayers 
would benefit if more of that budget were spent on treatment 
options, rather than law enforcement expenses and the 
healthcare cost burden that comes from patients who 
develop cirrhosis, lung and cardiovascular disease, and a 
variety of cancers, not to mention the expense of emergency 
room visits for overdoses. 
The latest NHSDA (National Household Survey on Drug 
Abuse) report conducted by the Substance Abuse and Men-
tal Health Services Administration reported in July 2007 that 
nearly one in 12 full time workers in the US have serious 
enough drug/alcohol problems to require medical treatment. 
The 2008 National Survey of Drug Use and Health (NS-
DUH) estimated that approximately 7.2 million Americans 
were in need of treatment for illicit drug use. Unfortunately, 
most of these individuals do not seek treatment. However, 
for those who do seek treatment, the third and fourth most 
common substance abuse types are opiate pain reliever and 
heroin, respectively. Providing recovery help for addicts 
with pharmacological interventions has proven helpful. In 
20 million) in 2003 to 720,000 ($78 million) in 2007. Disul-
firam, naltrexone, and acamprosate prescriptions dominate 
the market (Mark, 2009). 
The leading cause of preventable deaths in the United 
States is cigarette smoking, with over 440,000 premature 
25 deaths occurring each year. Cigarette smoking is known to 
reduce appetite and increase the rate of cellular metabolism, 
leading to body mass stabilization or reduction. One of the 
main reasons for recidivism in persons trying to quit smok-
ing is the potential for weight gain, especially in women. 
30 Regardless of the varied findings of the many studies on 
smoking cessation and weight gain, the primary recommen-
dation has been to incorporate weight loss treatment with 
smoking cessation. Naltrexone (NTX) may be a potential 
weight loss drug candidate, especially in combination with 
35 bupropion (Greenway et al., 2009; Greenway et al., 2010; 
Ioannides-Demos et al., 2011); and the biochemical rela-
tionship between appetite and addictive craving is receiving 
increasing attention (Reece, 2011). Interesting positive clini-
cal results have been seen when women smokers are treated 
40 with a combination ofNTX and nicotine patches (Epperson 
et al., 2010; Roche et al., 2010; Shaw and al'Absi, 2010). 
Good clinical trial results and preclinical data have shown 
a reduction in amphetamine and methamphetamine use with 
NTX treatment (Grant et al., 2010; Haggkvist et al., 2009a; 
45 Haggkvist et al., 2009b; Karila et al., 2010). Studies with 
many other drugs have shown a lack of success for meth-
amphetamine dependence treatment, therefore NTX may be 
a very good option (Karila et al., 2010). 
Naltrexone (NTX), an opioid antagonist, is currently 
50 prescribed as an oral tablet or 30-day depot injection form to 
help maintain opioid addicts in a drug-free state. Unfortu-
nately, postmarketing reports of serious injection site reac-
tions ( cellulitis, abscess, and necrosis) have recently 
required patient warning updates for the depot injection, and 
55 the oral dosage form is associated with many gastrointestinal 
side effects. NTX is also FDA-approved for the treatment of 
alcohol dependence. Substantial clinical evidence exists for 
the benefits of NTX treatment in smoking cessation, espe-
cially in women. Very intriguing clinical trial data has also 
60 been observed in amphetamine-dependent individuals, 
which is especially important as methamphetamine depen-
dence has no FDA-approved treatment options. Preclinical 
data also exists that suggests that NTX may benefit anabolic 
androgenic steroid dependency. Treatment with NTX in the 
65 90's produced variable success rates in addicts; however, 
current clinical NTX therapy is being optimized based on 
human pharmacogenetic data. 
US 9,566,341 Bl 
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Transdermal delivery of NTX is desirable for addicts in 
order to help reduce side effects associated with oral (hepa-
totoxicity at high doses in hepatocompromised addicts) and 
injectable therapies, and improve compliance. Permeation 
through the skin allows the drug to directly enter the 
systemic circulation and avoid the first pass effect. NTX 
itself does not have the essential physicochemical properties 
that would allow a therapeutic dose of the drug to cross the 
human skin barrier. 
Microneedle (MN)-enhanced transdermal delivery is an 
efficient and painless method for increasing the skin perme-
ation of many drugs, including NTX. The major limitation 
of MN-enhanced delivery is that the micropore lifetime only 
allows delivery of drug for two to three days. Therapeutic 
viability ofNTX treatment would be improved by a product 
that allows for less-frequent treatment. 
Accordingly, there remains a need in the art for novel 
compounds and methods that allow for a therapeutically 
successful drug delivery system that allows for less-frequent 
administration. 
SUMMARY 
The presently-disclosed subject matter meets some or all 
of the above-identified needs, as will become evident to 
those of ordinary skill in the art after a study of information 
provided in this document. 
This Summary describes several embodiments of the 
presently-disclosed subject matter, and in many cases lists 
variations and permutations of these embodiments. This 
Summary is merely exemplary of the numerous and varied 
embodiments. Mention of one or more representative fea-
tures of a given embodiment is likewise exemplary. Such an 
embodiment can typically exist with or without the 
feature(s) mentioned; likewise, those features can be applied 
to other embodiments of the presently-disclosed subject 
matter, whether listed in this Summary or not. To avoid 
excessive repetition, this Summary does not list or suggest 
all possible combinations of such features. 
Cyclooxygenase (COX) enzyme inhibitors, such as 
diclofenac, can prolong the lifetime of micropores of 
microneedle (MN)-enhanced transdermal delivery systems, 
allowing delivery of a drug to extend beyond a few days, 
allowing for less-frequent patch dosing (e.g., once a week). 
Many of the COX inhibitors are weak acids, and opioid 
antagonists, such as naltrexone and naltrexol, and many 
other desirable transdermal drugs are weak bases. It is 
difficult to formulate high concentrations of a weak base and 
a weak acid in the same system, due to chemical stability and 
solubility issues. 
The presently-disclosed subject matter includes com-
pounds including a first moiety derived from an drug of 
interest; and a second moiety derived from a cyclooxy-
genase (COX) enzyme inhibitor, wherein the first moiety is 
linked to the second moiety to form a single chemical entity. 
The compounds of the presently-disclosed subject matter 
improved microneedle-enhanced delivery rates across skin, 
as well as an increase in the pore lifetime or duration of 
delivery. Without wishing to be bound by theory or mecha-
nism, the cox inhibitor component of the compound allows 
for pores to remain open for a longer time period, allowing 
for improved delivery of the first moiety/drug of interest. In 
some embodiments, the first moiety is derived from a drug 
with a phenolic hydroxyl or hydroxyl group. In some 
embodiment, the first moiety is derived from an opioid. In 
some embodiments, the first moiety is derived from an 
opioid antagonist. 
4 
Compounds of the presently-disclosed subject matter are 
useful for use in a therapeutically-successful delivery system 
that allows for less-frequent dosing. In some embodiments, 
the compounds can be used in an MN transdermal delivery 
system to provide a therapeutic transdermal delivery rate of 
an opioid antagonist (e.g., naltrexone or naltrexol). Contem-
plated delivery rates across the skin are improved because of 
optimized physicochemical properties for faster diffusion. 
In some embodiments, the opioid from which the first 
10 moiety is derived is selected from: naltrexone, buprenor-
phine, butorphanol, codeine, cyclazocine, cyclorphan, 
oxilorphan, dihydrocodeine; dihydromorphine, ethymor-
phine, hydromorphone, levallorphan, levorphanol, nalbu-
phine, nalmefene, nalorphine, naloxone, naltrexol, phenazo-
15 cine, and pholcodine. In some embodiments, the opioid 
antagonist is naltrexsone or naltrexol. 
In some embodiments, the COX enzyme inhibitor from 
which the second moiety is derived is selected from: 
diclofenac, SC560, valeryl salicylate, mofezolac, 
20 FR122047, celecoxib, ibuprofen, and ketoprofen. In some 
embodiments, the COX enzyme inhibitor is diclofenac. 
In some embodiments, the opioid from which the first 
moiety is derived is selected from: naltrexone, buprenor-
phine, butorphanol, codeine, cyclazocine, cyclorphan, 
25 oxilorphan, dihydrocodeine, dihydromorphine, ethymor-
phine, hydromorphone, levallorphan, levorphanol, nalbu-
phine, nalmefene, nalorphine, naloxone, naltrexol, phenazo-
cine, and pholcodine; and the COX enzyme inhibitor from 
which the second moiety is derived is selected from: 
30 diclofenac, SC560, valeryl salicylate, mofezolac, 
FR122047, celecoxib, ibuprofen, and ketoprofen. 
In some embodiments, the opioid antagonist is naltrexone 
or naltrexol and the COX enzyme inhibitor is diclofenac. 
In some embodiments, the compound includes a linker 
35 moiety. In some embodiments, the opioid antagonist and the 
COX enzyme inhibitor are linked by a linker moiety. In 
some embodiments, the linker moiety is cleavable. In some 
embodiments, the linker moiety is cleavable by hydrolysis 
and/or enzymatic digestion. In some embodiments, the 
40 linker moiety inparts improved aqueous solubility to the 
compound. 
In some embodiments, the compound comprises a struc-
ture selected from a structure as set forth in FIG. 2. 
The presently-disclosed subject matter further includes a 
45 method for treating a subject, including identifying a subject 
in need of treatment for a condition selected from the group 
consisting of pain, depression, narcotic dependence, alcohol 
dependence, amphetamine dependence, smoking depen-
dence, and anabolic-androgenic steroid dependence; and 
50 delivering to the subject a therapeutically effective amount 
of a compound of the presently-disclosed subject matter. 
In some embodiments, a method for treating a subject 
includes identifying a subject in need of treatment for a 
condition selected from the group consisting of pain, depres-
55 sion, narcotic dependence, alcohol dependence, amphet-
amine dependence, smoking dependence, and anabolic-an-
drogenic steroid dependence; and delivering to the subject a 
therapeutically effective amount of a compound of the 
presently-disclosed subject matter, wherein following deliv-
60 ery to the subject, the compound is transformed into at least 
two active drug molecules. In some embodiments, the 
transformation is by hydrolysis and/or enzymatic digestion. 
The compound can be delivered in a variety of manners. In 
some embodiments, the compound is delivered transder-
65 mally. 
In some embodiments, the compound can be transder-
mally delivered by microneedle, wherein the compound 
US 9,566,341 Bl 
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microneedles that had pores that closed up did not show this 
type of staining, so the effect means the pores are viable. 
This technique has been used by others to visualize micropo-
res in other studies. Pores heal quickly after the patches are 
removed (Banks et al., 2010). 
FIG. 10 is a graph showing how plasma concentration 
changes with a change in flux rate. 
achieves improved duration of microporation-assisted deliv-
ery of the drug of interest (from which the first moiety of the 
compound is derived), as compared to the parent drug of 
interest (as administered independent from the compound 
including first and second moieties as described herein). In 5 
some embodiments, the improvement of duration of 
microporation-assisted delivery of the drug of interest (e.g., 
from a single patch) is an improvement of greater than 1, 2, FIG. 11 Solubility profile of naltrexone and diclofenac 
generated using predicted chemical property values from 
10 Scifinder®. 
3, 4, 5, 6, or 7 days. 
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 12 Structure of parent drugs, (a) naltrexone, (b) 
diclofenac (c) 3-0-ester codrug and (d) hydrochloride salt 
form of 3-0-ester codrug. FIG. 1 is a graph showing solubility of naltrexone and 
diclofenac as a function of pH; pH 5 is the ideal value for 
topical formulation. 
FIGS. 2A-2W are structures of exemplary embodiments 
of compounds of the presently-disclosed subject matter, 
where n is 1, 2, 3, or 4 in FIGS. 2C-2J, 2M, and 2N, and n 
FIG. 13 Stability study profile for codrug in hairless 
15 guinea pig plasma indicating pseudo first order kinetics. 
(n=3). 
is 4, 5, or 6 in FIGS. 2K and 2L. 
FIG. 14 In vitro diffusion study across full thickness 
Yucatan miniature pig skin of the base form of the com-
pound of FIG. 2U (A) Steady state flux of naltrexone and 
FIG. 3 describes the specific decision making for com-
pounds of the presently-disclosed subject matter, as 
described in the present Examples. 
20 diclofenac from the codrug at 48 hours post MN treatment. 
(n=3) (B) Skin concentration over time from the base form 
of the compound of FIG. 2U. Both naltrexone and 
diclofenac concentration could be observed in the skin FIG. 4 is a graph showing NTX flux comparison from a 
human study with MN and NTX patches (Wermeling et al., 
2008), the compound of FIG. 2A (codrug) salt, and an 25 
optimized NTX HCl formulation with 10% propylene glycol 
(PG). The human study used 60% PG, which causes a 
decrease in flux due to the viscosity increase (Milewski and 
Stinchcomb, 2011). The optimized NTX HCl flux is a target 
for embodiments of the compound. 
indicating the regeneration of the parent molecules. n=3 for 
12 h, 24 hand n=2 for 36 hand 48 h. 
FIG. 15 In vitro diffusion study across full thickness 
Yucatan miniature pig skin comparing the base form on the 
codrug to the hydrochloride salt form. The steady state flux 
values of naltrexone are reported from codrug base (n=3) 
30 and codrug salt (n=4). 
FIG. 5 is a graph showing skin concentrations of 
diclofenac after treatment with Solaraze gel in Yucatan 
miniature pig skin in vitro with MN treatment and non-MN 
treated controls. Daily application of Solaraze was applied 
to the skin to mimic the in vivo hairless guinea pig study 35 
where microneedle treated pores stayed open for 7 days 
(FIG. 7). 
FIG. 16 includes a graph showing flux ofnaltrexone from 
different formulations of the compound of FIG. 2U. In vitro 
diffusion study across full thickness Yucatan miniature pig 
skin comparing the flux of naltrexone at steady state from 
different donor formulations. Propylene glycol (PG) was 
used in different concentrations to optimize formulation for 
in vivo studies (n;;,;3) 
FIG. 17 is a series of pictures of visualized hairless guinea 
pig micropores (A) immediately following MN treatment, 
(B) at day 4 following treatment with MN followed by 
application of NTX HCl gel under occlusion, and (C) 
visualized by India ink staining wherein the HCl salt form of 
the compound was used following MN treatment indicating 
that the pores can stay open up to a 7 day time point. 
FIG. 18 is a graph showing flux of NTXol in a study 
involving the compound of FIG. 2V. 
FIG. 6 includes graphs showing skin concentrations in 
Yucatan miniature pig skin in vitro after MN treatment and 
application of the compound of FIG. 2A (codrug). Experi- 40 
ments were terminated and skin disposition measured at 12, 
24, 36, and 48 h. Flux values correlated with the skin 
disposition data, as the flux of NTX from the codrug was 
twice as high as the diclofenac flux, further proving the 
higher retention of diclofenac in the skin. The flux of NTX 45 
was also measured over 48 h from the compound of FIG. 2A 
and its HCl salt. FIG. 19 In vitro diffusion study across full thickness 
Yucatan miniature pig skin comparing the flux of naltrexone 
at steady state from naltrexone HCl, salt form of the codrug 
50 and previously studied formulation for in vivo human phar-
macokinetic studies (n>3). 
FIG. 7 is a graph showing NTX plasma levels in hairless 
guinea pigs after application of NTX gel alone or NTX gel 
and Solaraze ( diclofenac gel). A control containing the 
hyaluronic acid in Solaraze was also tested, and an extension 
in micropore lifetime was not observed. No significant 
depletion from the NTX control gel was identified, as only 
a few percent of the total drug was delivered (Banks et al., 
2011). 
FIG. 8 is a graph showing NTX plasma concentrations in 
Yucatan miniature pig (n=3 trials) after topical dosing for 72 
55 
h with an NTX hydrogel and a single MN application. Time 
points from 72 to 96 hours are after patch removal. No NTX 
was detected when the same formulation (& patch area) 60 
applied to the pig without MN treatment. Similar to human 
results, showing the need for micropore closure inhibition. 
Intravenous NTX was evaluated in the pigs in order to 
determine the clearance of NTX and NTXOL. 
FIG. 9 is a picture of hairless guinea pig micropores 65 
visualized with India ink at the end of the 7 day experiment 
with the compound of FIG. 2A (codrug). Skin treated with 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The presently-disclosed subject matter includes com-
pounds including a first moiety derived from a drug of 
interest; and a second moiety derived from a cyclooxy-
genase (COX) enzyme inhibitor, wherein the first moiety is 
linked to the second moiety to form a single chemical entity. 
Compounds of the presently-disclosed subject matter are 
sometimes referred to herein as codrugs. A codrug com-
prises two different drugs within a single chemical entity. 
The two drugs may be connected either directly or by means 
of a cleavable, biolabile covalent linker. Many diseases are 
treated by a combination of therapeutic agents that are 
co-administered in separate dosage forms. However; there 
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are potential advantages in delivering the co-administered 
agents as a single chemical entity. One advantage is that 
often, when the two drugs are chemically linked together in 
the codrug structure, the resulting physicochemical and 
pharmacokinetic properties of the codrug are superior to 
those of the individual parent drugs. 
8 
In some embodiments, the opioid antagonist and the COX 
enzyme inhibitor are joined by a linker moiety or more than 
one linker moiety. The linker moiety(ies) can be a cleavable 
linker moiety(ies) such as ester, thioester, carbonate, car-
bamate, thiocarbamate, amide, thioamide, ureide, or any 
other suitable chemical moieties, providing that the chem-
istry is feasible. It will be recognized by the skilled artisan 
that desirable linker moieties can be bioconvertible or bio-
labile. In some embodiments the linker moiety(ies) is cleav-
10 able via hydrolysis or enzymatic digestion. 
The term "derived from" indicates that the first and 
second moieties of the compounds have a structure of a 
parent drug of interest and COX inhibitor that have been 
modified as is necessary to be connected to the remainder of 
the compound, while maintaining some or all of the activity 
associated with the parent compound, or while obtaining 
enhanced activity relative to the parent compound. For 
example, a moiety derived from a drug of interest and COX 
15 
inhibitor can have the structure of the drug of interest and 
COX inhibitor, less a leaving group (e.g., less a hydrogen, 
less a hydroxyl, less a covalent bond, or less another leaving 
group) or including a connecting group, as will be apparent 
Exemplary compounds of the presently-disclosed subject 
matter are set forth in FIGS. 2A-2W. 
The presently disclosed subject matter also includes meth-
ods of treating a subject for conditions including pain, 
depression, and substance dependence, including narcotic 
dependence, alcohol dependence, amphetamine depen-
dence, smoking dependence, and anabolic-androgenic ste-
roid dependence. As used herein, dependence is inclusive of 
addiction and is inclusive of any disorder associated with 
to one of ordinary skill in the art. 
The compounds of the presently-disclosed subject matter 
provide for improved microneedle-enhanced delivery rates 
across skin, as well as an increase in the pore lifetime or 
duration of delivery. Without wishing to be bound by theory 
20 dependence and/or addiction; as such, alcohol dependence, 
for example, is inclusive of alcohol abuse and alcoholism. 
or mechanism, the cox inhibitor component of the com- 25 
pound allows for pores to remain open for a longer time 
period, allowing for improved delivery of the first moiety/ 
drug of interest. In some embodiments, the first moiety is 
derived from a drug with a phenolic hydroxyl or hydroxyl 
group. In some embodiment, the first moiety is derived from 30 
an opioid. In some embodiments, the first moiety is derived 
from an opioid antagonist. 
Exemplary first moieties of the compounds of the pres-
ently-disclosed subject matter can be derived from opioids 
including, but not limited to naltrexone, buprenorphine, 35 
butorphanol, codeine, cyclazocine, cyclorphan, oxilorphan, 
dihydrocodeine, dihydromorphine, ethymorphine, hydro-
morphone, levallorphan, levorphanol, nalbuphine, nalme-
fene, nalorphine, naloxone, naltrexol (including 6-beta nal-
trexol and 6-alpha naltrexol), phenazocine, and pholcodine, 40 
and other opioids known to those skilled in the art. 
In some embodiments, a method of the presently-dis-
closed subject matter includes identifying a subject in need 
of treatment for a condition selected from the group con-
sisting of pain, depression, narcotic dependence, alcohol 
dependence, amphetamine dependence, smoking depen-
dence, and anabolic-androgenic steroid dependence; and 
delivering to the subject a therapeutically effective amount 
of a compound of the presently-disclosed subject matter. 
Without wishing to be bound by mechanism, following 
delivery to the subject, the compound is transformed into at 
least two active drug molecules. 
Subjects who can benefit from the methods of the present 
invention include, for example, mammals, such as humans, 
particularly humans who are suffering from pain, depres-
sion, and/or substance dependence. 
"Treatment" or "treating," as used herein, refers to com-
plete elimination as well as to any clinically or quantitatively 
measurable reduction in condition for which the subject is 
being treated. The methods of the presently-disclosed sub-
ject matter include delivering a therapeutically effective 
amount of the compound. A "therapeutically effective 
amount," as used herein, refers to an amount, determined by 
one skilled in the art, sufficient for treating the condition for 
which the subject is being treated. 
The compound can be delivered to a subject transder-
mally, intravenously, orally, buccally, sublingually, by topi-
cal creams, subdermally, as a sustained release depot, oph-
thalmically, intranasally, aurally, by inhalation, rectally or 
Exemplary second moieties of the compounds of the 
presently-disclosed subject matter can be derived from COX 
enzyme inhibitors including, but not limited to diclofenac, 
SC560, valeryl salicylate, mofezolac, FR122047, celecoxib, 45 
ibuprofen, ketoprofen, and other COX inhibitors known to 
those skilled in the art, including non-steroidal anti-inflam-
matory drugs (NSAIDs), COX-1 inhibitors and COX-1-
specific inhibitors, and COX-2 inhibitors and COX-2-spe-
cific inhibitors. 50 vaginally. 
In some embodiments of the compound, the opioid 
antagonist is naltrexone or naltrexol, and the COX enzyme 
inhibitor is selected from diclofenac, SC560, valeryl salicy-
late, mofezolac, FR122047, celecoxib, ibuprofen, and keto-
profen. In some embodiments of the compound, the opioid 
antagonist is naltrexone or naltrexol, and the COX enzyme 
inhibitor is diclofenac. In some embodiments of the com-
pound, the opioid antagonist is naltrexol and the COX 
enzyme inhibitor is diclofenac. 
In some embodiments, the compound has more than one 
first moiety derived from an opioid antagonist and/or more 
than one second moiety derived from a COX inhibitor, 
wherein each of the first moieties and each of the second 
In some embodiments, transdermal delivery is used. In an 
exemplary method for transdermal delivery of the com-
pound, the steps comprise contacting a section of skin with 
the compound and biotransforming the compound into two 
55 drugs by skin enzymes or by hydrolysis of the compound in 
the skin. A transdermal patch comprising a suitable substrate 
and a layer of the compound can be employed to deliver the 
compound to the skin. 
The compound can be administered as a pharmaceutical 
60 composition comprising pharmaceutically acceptable carri-
ers, diluents, and/or excipients, which are vehicles com-
monly used to formulate pharmaceutical compositions for 
animal or human administration. The carriers, diluents and/ 
moieties are independently selected (e.g., each of the more 
than one first moieties need not be derived from the same 65 
or excipients are not intended to have biological activity 
themselves, and are selected so as not to affect the biological 
activity of the compound and any other active agent(s). A opioid antagonist and/or each of the more than one second 
moieties need not be derived from the same COX inhibitor. pharmaceutically acceptable carrier, diluent, and/or excipi-
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ent as used herein includes both one and more than one such 
carrier, diluent, and/or excipient. Examples include but are 
not limited to distilled water, saline, physiological phos-
phate-buffered saline, Ringer's solutions, dextrose solution, 
and Hank's solution. Depending upon the manner of intro-
duction, the compound can be formulated as, for example, a 
sterile injectable formulation comprising aqueous solutions 
and/or suspensions containing the active materials in admix-
ture with suitable carriers, diluents, and/or excipients. 
10 
7 days. Such a bandage, pad, or other type of patch which 
can be used in the practice of the method of the present 
invention can take the form of an occlusive body. In practice, 
the occlusive body which includes the compound is posi-
tioned on the subject's skin under conditions effective to 
transdermally deliver the compound to the subject's skin. 
The concentration of compound, the formulation (i.e., a 
formulation that is therapeutically effective to the subject to 
which it is administered) and the dose administered can be 
readily determined by a person of ordinary skill in the art. 
Typically, dosages used in vitro and in animal models, such 
In some embodiments, the methods of the presently-
disclosed subject matter can make use oftransdermal deliv-
ery using microneedles. The microneedle strategy suitable 
10 for use in the presently-disclosed subject matter is not 
particularly limited, but includes any microneedle strategy 
that can be employed to facilitate the transdermal delivery of 
compounds described herein. 
as in the experiments provided in the present application, 15 
can provide useful guidance in the amounts useful for in 
vivo administration. 
The compound can be applied to the skin as a topical 
cream, salve, ointment, gel, or other topical formulation; 
and/or by using delivery devices such as bandages, occlu- 20 
sive bodies, patches, and/or the like. The area of skin to 
which the compound is applied can optionally be pre-treated 
with microneedles or other microporation devices, as are 
known to those of ordinary skill in the art. 
As used herein, the term "microneedles" refers to a 
plurality of elongated structures that are sufficiently long to 
penetrate through the stratum corneum skin layer and into 
the epidermal/dermal layer, yet are also sufficiently short to 
not activate nerve endings and cause pain. 
Various microneedles that can be employed to facilitate 
transdermal delivery of compounds of the presently-dis-
closed subject matter are described in printed publications 
and are known to those of ordinary skill in the art. Suitable 
microneedles have been fabricated from many materials, 
Illustratively, a composition of the compound that is 
applied to the skin can be formulated as a topical cream, 
salve, gel, or ointment. The topical formulations can include 
inert diluents and carriers as well as other conventional 
excipients, such as wetting agents, preservatives, and sus-
pending and dispersing agents. In addition to the above, 
generally non-active components, topical formulations con-
taining compound can further include other active materials, 
particularly, active materials which have been identified as 
useful in the treatment of the condition for which the subject 
25 including silicon, metals, and polymers. 
The microneedles can be solid or hollow. If solid 
microneedles are used, channels can be made by poking the 
skin with a microneedle array, followed by removal of the 
needles and then application of the drug. Alternatively, the 
30 solid microneedles can be inserted and left in the skin, 
allowing diffusion through the gaps between the 
microneedles and the surrounding tissue. Solid microneedles 
can also be coated with the compound prior to insertion into 
the skin. Alternatively, microneedles containing a hollow 
35 bore can be used to transport drugs through the interior of 
the needles by diffusion or pressure-driven flow. Hollow 
microneedles can act as mini hypodermic injection needles. 
is being treated, for example substance addiction, and which 
can usefully be delivered transdermally to the subject. For 
instance, such other active materials can include acampro-
sate, disulfiram, topiramate, sertraline, rivastigmine, citalo-
pram, and doxepin. The topical formulation can be applied 
directly to the skin and then optionally covered (e.g., with a 
bandage of gauze) to minimize the likelihood of its being 
disturbed. Alternatively, the topical formulation can be 
coated on the surface of a bandage, gauze, etc., and the 
bandage, gauze, etc. can then be applied to the skin of the 
subject such that the topical formulation is in direct contact 45 
with the subject's skin. 
In some embodiments, the microneedles can be used to 
create a microneedle-treated site prior to applying the com-
40 pound to the microneedle-treated site. As noted above, the 
microneedles can be inserted and left in the skin. In some 
embodiments, a microneedle array comprised of solid 
microneedles can be used to increase skin permeability by 
inserting the microneedles into the skin and then removing 
the microneedles to create a microneedle-treated site prior to 
applying the compound to the microneedle-treated site. 
Optionally, the microneedles can be repeatedly inserted and 
removed, at the same site. Typical microneedle arrays com-
prise 15-200 microneedles, but can include any number of 
Alternatively, the compound can be delivered transder-
mally to the subject by formulating compound into a ban-
dage, pad, or other type of patch which can be applied to the 
subject's skin. 50 microneedles that is desired. 
The microneedles can be inserted and removed to create 
a microneedle-treated site on the subject's skin under con-
ditions effective to transdermally deliver the compound 
upon application of the compound. Such conditions can 
include, for example, positioning the microneedle-treated 
site on a portion of the subject's skin which is not covered 
with hair, and/or shaving the hair from the selected portion 
of the subject's skin. 
The details of one or more embodiments of the presently-
Illustratively, matrix-type transdermal patches, in which 
the compound is disposed in an adhesive matrix, can be 
employed. The matrix-type transdermal patch can further 
include other active materials for transdermal delivery to the 
subject with the compound. Suitable adhesives for use in 55 
such matrix-type transdermal patches include polyisobuty-
lenes, acrylates, silicone, hydrogels, and combinations 
thereof. Still other patches suitable for use in the practice of 
the present invention are known to those of ordinary skill in 
the art. 60 disclosed subject matter are set forth in this document. 
In another illustrative embodiment, the bandage, pad, or 
other type of patch can be one which is capable of control-
ling the release of the compound such that transdermal 
delivery of the compound to the subject is substantially 
uniform and sustained over a period of at least 12 hours, 
such as at least 24 hours, at least 48 hours, at least 3 days, 
at least 4 days, at least 5 days, at least 6 days, and/or at least 
Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
skill in the art after a study of the information provided in 
this document. The information provided in this document, 
65 and particularly the specific details of the described exem-
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 
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understood therefrom. In case of conflict, the specification of 
this document, including definitions, will control. 
While the terms used herein are believed to be well 
understood by one of ordinary skill in the art, definitions are 
set forth to facilitate explanation of the presently-disclosed 
subject matter. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
presently-disclosed subject matter belongs. Although any 
methods, devices, and materials similar or equivalent to 
those described herein can be used in the practice or testing 
of the presently-disclosed subject matter, representative 
methods, devices, and materials are now described. 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer-
ence to "a cell" includes a plurality of such cells, and so 
forth. 
Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 
desired properties sought to be obtained by the presently-
disclosed subject matter. 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia-
tions of in some embodiments ±20%, in some embodiments 
±10%, in some embodiments ±5%, in some embodiments 
±1%, in some embodiments ±0.5%, and in some embodi-
ments ±0.1 % from the specified amount, as such variations 
are appropriate to perform the disclosed method. 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
For example, ifthe value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
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and development for improved pharmacologic treatments 
for drug and alcohol abuse are very important. Naltrexone 
(NTX), an opioid antagonist, is currently prescribed in oral 
tablet and injectable form to help maintain opioid addicts in 
a drug free state. Most recently, naltrexone has been indi-
cated as an adjunct in the treatment of alcohol dependence, 
as well as reported to reduce alcohol craving in certain 
alcoholic populations. Unfortunately, postmarketing reports 
of serious injection site reactions ( cellulitis, abscess, and 
10 necrosis) have recently required patient warning updates for 
the 30-day NTX depot injection. Additionally, high oral 
doses that may be needed for therapeutic effect in addicts 
can cause hepatotoxicity. Substantial clinical evidence exists 
15 
for the benefits of NTX treatment in smoking cessation, 
especially in women (Epperson et al., 2010; Roche et al., 
2010; Shaw and al'Absi, 2010; Toll et al., 2010). Very 
intriguing clinical trial data has also been observed in 
amphetamine dependent individuals, which is especially 
20 important as methamphetamine dependence has no FDA-
approved treatment options (Grant et al., 2010; Haggkvist et 
al., 2009a; Haggkvist et al., 2009b; Karila et al., 2010). 
Preclinical data also exists that suggests that NTX may 
benefit anabolic-androgenic steroid dependent people (Ka-
25 nayama et al., 2010a; Kanayama et al., 2010b). Treatment 
with NTX in the 90's and early 2000's produced variable 
success rates in addicts; however, current clinical NTX 
therapy is being optimized based on human pharmacoge-
netic data (Barr et al., 2010; Fortin et al., 2010; Ray et al., 
30 2010a; Ray et al., 2010b). Transdermal delivery ofnaltrex-
one is desirable for addicts and alcoholics in order to help 
reduce side effects associated with oral (bypass first-pass 
effect) and injectable therapy and improve compliance. 
Naltrexone itself does not have the essential physicochemi-
35 cal properties that would allow a therapeutic dose of the drug 
to cross the human skin barrier. Microneedle-enhanced 
transdermal delivery is an efficient and painless method for 
increasing the skin permeation of many drugs, including 
naltrexone (Prausnitz, 2004; Wermeling et al., 2008). The 
40 major limitation of microneedle-enhanced delivery is that 
the micropore lifetime only allows delivery of drug for two 
to three days (Banks et al., 2010; Milewski et al., 2010; 
Wermeling et al., 2008). 
two particular units are also disclosed. For example, if 10 
and 15 are disclosed, then 11, 12, 13, and 14 are also 45 
disclosed. 
Diclofenac and other relevant cyclooxygenase (COX) 
enzyme inhibitors can prolong the lifetime of the micropores 
to seven days, allowing for once a week patch dosing, the 
transdermal delivery ideal goal (Banks et al., 2011 ). Many of 
the COX inhibitors are weak acids, and naltrexone and many 
other desirable transdermal drugs are weak bases. It is 
The presently-disclosed subject matter is further illus-
trated by the following specific but non-limiting examples. 
The following examples may include prophetic descriptions, 
and/or compilations of data and information that are repre-
sentative of data and information gathered at various times 
during the course of development and experimentation 
related to the present invention. 
EXAMPLES 
Example 1 
An objective of the exemplary studies described herein 
include improvement of drug therapy for opioid, smoking, 
methamphetamine, alcohol and other relevant addiction 
recovery by creating transdermal dosage form with longer 
intervals between dosing, e.g., at least 7-day (once-a-week 
dosing). 
Alcoholism and drug addiction lead to major health-
related problems and societal costs for people in the United 
States and the rest of the world as well. Therefore, research 
50 difficult to formulate high concentrations of a weak base and 
a weak acid in the same system, due to chemical stability and 
solubility issues. The present inventors disclose herein com-
positions (sometimes referred to herein as codrugs), which 
are covalently linked yet biolabile combinations of an opioid 
55 antagonist (e.g., naltrexone) and a COX inhibitor (e.g., 
diclofenac ), in order to make a therapeutically successful 
once a week drug delivery system. It is contemplated that 
codrugs of naltrexone in combination with microneedle 
treatment will provide a 7-day therapeutic transdermal deliv-
60 ery rate of naltrexone, and that these codrugs will make 
excellent research tools for investigating quantitative struc-
ture permeability relationships (QSPR) for transdermal flux 
and optimization of flux and micropore lifetime in combi-
nation with microneedle enhancement. These codrugs/mi-
65 croneedles should improve naltrexone delivery rates across 
the skin because of optimized physicochemical properties 
for faster diffusion. 
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A series compounds (FIG. 2) were designed to elucidate 
fundamental QSPRs for microneedle-enhanced transdermal 
flux optimization and subsequent bioconversion rates. Char-
acterization of the physicochemical properties of the cod-
rugs, including molecular volume, lipophilicity, hydrogen-
bonding potentials, melting points, heats of fusion, 
hydrolysis kinetics, and solubilities in select solvents is 
contemplated. The present inventors also contemplate mea-
suring the drugs' penetration, concurrent bioconversion, and 
COX inhibitor deposition in skin in vitro with microneedle 
use. Also contemplated is characterization of the pharma-
cokinetics of the compounds in animals (e.g., guinea pigs 
and Yucatan miniature pigs in vivo, and humans) with 
microneedle use. Correlation of the in vitro data with the in 
vivo model will aid in the creation of a reliable QSPR 
database that is useful to determine relative efficacy of 
compounds for clinical use. The studies will incorporate a 
parallel pharmacodynamic (micropore closure) and drug 
delivery/pharmacokinetic approach to identify novel codrug 
treatments for significant clinical problems, such as opiate, 
smoking, methamphetamine and alcohol addiction. 
As noted herein naltrexone (NTX) is an opioid antagonist 
that is currently used to help maintain opioid addicts in a 
drug-free state. Most recently, naltrexone has been indicated 
for use in treatment of other substance dependencies, e.g., 
alcohol dependence, including use to reduce alcohol craving 
in certain alcoholic populations (Garbutt, 201 O; Gue-
orguieva et al., 2010; Martinotti et al., 2010; Morley et al., 
2010; O'Malley, 1996; O'Malley et al., 1992; Soyka and 
Rosner, 2010; Volpicelli et al., 1992; Zarkin et al., 2010). 
Pharmacogenetic analysis has been shown to improve NTX 
treatment outcomes in clinical trials for alcoholism (Barr et 
al., 2010; Fortin et al., 2010; Kranzler and Edenberg, 2010; 
Kranzler et al., 2000; Ray et al., 2010a; Ray et al., 2010b). 
NTX Hydrochloride is currently commercially available in 
the United States as a 50-mg oral tablet (ReVia®), as well 
as in generic form. Naltrexone undergoes extensive first-
pass metabolism and has oral bioavailability estimates rang-
ing from five to forty percent (PDR). Naltrexone is also a 
hepatotoxin that has the capacity to cause dose-related 
hepatocellular injury. This hepatotoxicity limits dosage 
increases in those addicts who may benefit from more than 
14 
injection or patch treatment. In contrast to depot dosage 
forms, transdermal systems offer a patient freedom from 
injections (a 380 mg NTX as 1.1 g microsphere intramus-
cular injection), surgical implantations, and the healthcare 
costs associated with implant dosing. Injection site reactions 
are one of the most common Vivitrol adverse events. 
Another advantage of transdermal dosing is the ability to 
terminate the drug dose input at any time by simply remov-
ing the patch. The process of terminating drug input from the 
10 depot injection requires surgical removal of microspheres 
from the muscle, which might be necessary if a patient 
requires opiate treatment for pain in an emergency situation 
that occurs within the 30-day window where plasma levels 
of naltrexone are released. A transdermal patch provides 
15 sustained-release of a drug for a maximum of about one 
week. Once-a-week dosing is certainly more desirable than 
the three to seven times a week dosing of the currently 
available ReVia®. The transdermal patch delivery system 
suits the addict population well, being similar to the patch-
20 wearing population of nicotine addicts. A transdermal sys-
tem that delivered a therapeutic dose of naltrexone into the 
body for one week would certainly be consistent with a 
weekly visit to an addict recovery clinic or probation officer. 
As compliance is the major concern in nonmotivated crimi-
25 nal addicts, use of an adhesive that sticks to the skin only 
once could be a helpful clue for a probation officer looking 
for the noncompliant addict. This could deter an addict from 
removing his/her patch during the week, knowing that 
punishment for showing up with a non-stick patch would be 
30 likely. 
A very promising use of a transdermal NTX system is as 
an adjunct in the treatment of alcohol dependence. Trans-
dermal delivery of the potential hepatotoxin naltrexone will 
bypass first-pass liver metabolism and also decrease gastro-
35 intestinal side effects. A relatively motivated alcoholic 
would certainly want the ease of use and reduction of side 
effects possible with transdermal delivery. In fact, compli-
ance has been a critical issue in the response of alcoholics to 
naltrexone therapy in recent clinical trials (Volpicelli et al., 
40 1997). Alcohol use has been shown to decrease by about 
one-half in adult alcoholics taking naltrexone (Pettinati et 
al., 2010; Volpicelli et al., 1997). Additionally, there is one 
case report of an adolescent male that describes 30-day 
abstinence during naltrexone alcohol-dependence treatment. 
a 50-100 mg per day oral dose. Transdermal delivery would 
circumvent these liver-related problems by allowing lower 
doses to be used, because first-pass metabolism is bypassed. 
Certainly, the ability to decrease the drug dosage would 
benefit the already hepato-compromised alcoholic or nar-
cotic addict. Many of the adverse effects seen with Re Via® 
oral therapy (abdominal pain, constipation, nausea, and 
vomiting) could also be reduced by transdermal therapy. 50 
Compliance, the major problem with addict recovery phar-
macological intervention, is likely improved when side 
effects are reduced and drug doses are adequate to reduce 
craving (O'Malley, 1996; O'Malley et al., 1992). One goal 
45 The prevalence rate of adolescent alcohol dependence 
appears to be about four to ten percent, according to some 
self-reported epidemiological studies. Thus, transdermal 
delivery of naltrexone may also prove useful in the adoles-
cent alcohol-dependent population, as well as in adults. 
Naltrexone itself does not have the essential physico-
chemical properties that would allow a therapeutic dose of 
the drug to cross the human skin barrier. Prodrugs contain 
covalently bound chemical moieties added to a drug to make 
it more permeable, but these prodrugs are rapidly biocon-
of this research is to enhance the therapeutic value of 
naltrexone by reducing side effects and improving addict 
compliance with transdermal delivery that allows for dosing 
of at least about 7 days. Several once-a-week transdermal 
patches are on the market and are very popular. 
55 verted back to the active parent compound after dosing or 
absorption. A codrug contains two active drug molecules 
covalently linked together to improve the delivery or other 
properties of one or both drugs (Kiptoo et al., 2006; Kiptoo 
et al., 2008; Strasinger et al., 2008). In this case, the acid 
60 functionality is being removed (temporarily masked) from 
one of the drugs by forming a codrug so that the weak acid 
COX inhibitor and the weak base NTX can be combined at 
high concentrations in one dosage form without stability or 
The major problems with addict naltrexone use are moti-
vation and compliance, which have prompted the develop-
ment of 30-day depot dosage forms (Garbutt et al., 2005; 
Kranzler et al., 2000). The depot dosage form (Vivitrol, 
approved by the FDA in the summer of 2006) has been 
shown to be effective in clinical trials with opiate addicts and 65 
alcoholics, which bodes well for the patch, as the plasma 
drug concentration profiles would be similar after depot 
solubility incompatibility issues (FIG. 1). The naltrexone 
delivery rate will be enhanced with codrugs designed to 
optimize microneedle-assisted delivery for NTX flux as well 
as micropore lifetime. 
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Verification of codrug NTX delivery enhancement with an 
applicable in vitro/in vivo transdermal delivery correlation 
will help identify the most promising codrug for eventual 
human use. This validation of in vitro/in vivo correlation 
will be especially important in microneedle-assisted deliv- 5 
ery, where optimal and efficient testing methods are just 
being developed for this new and rapidly growing area of 
drug delivery. Increased understanding of the quantitative 
structure-permeability relationships (QSPRs) for transder-
mal codrug flux and concurrent bioconversion in vivo will 10 
be attained by statistically comparing calculated codrug 
physicochemical parameters, experimentally-derived physi-
cochemical parameters, and diffusion study data. This way 
the data gathered here can be applied to the design of other 
transdermal codrugs for use with microneedle-assisted 15 
delivery. 
Skin Permeation: The skin consists of two major layers, 
the outer epidermis and the inner dermis. The stratum 
corneum, the outermost 10-15 µm of the epidermis, is 
responsible for the skin's excellent diffusional resistance to 20 
the transdermal delivery of drugs. Most of the skin's enzy-
matic activity lies in the basal cell layer of the viable 
epidermis. Many researchers (Potts et al., 1997; Potts and 
Guy, 1992; Roberts and Sloan, 1999) have developed skin 
permeability relationships based on the physicochemical 25 
parameters (molecular weight, molecular volume, lipophi-
licity, hydrogen-bonding potentials, polarity, etc.) of skin 
penetrants. In the proposed project, these useful permeabil-
ity models will be correlated with transdermal codrug dif-
fusion, while taking into account complications of concur- 30 
rent bioconversion of the codrug. 
Transdermal Prodrugs and Codrugs (Mutual Prodrugs): 
Studies performed by R. J. Scheuplein et al. in the 1960's 
spurred pharmaceutical scientists to make use of new infor-
mation concerning passive permeability and metabolism 35 
properties of the skin. Since transport is a highly restricting 
factor to successful topical use of drugs and since it is the 
physical properties of a drug that largely determine the upper 
limit to transport, attention was soon focused on manipu-
lating the physical properties of drugs to improve delivery. 40 
Models for evaluating transdermal prodrug delivery began 
to appear in the pharmaceutical literature in the late 1970's 
(Yu et al., 1979). Over the last thirty years some other 
scientists have described possible transdermal prodrug 
delivery for drugs such as fluorouracil, naproxen, acyclovir, 45 
indomethacin, morphine, estradiol, and theophylline. A few 
people have written comprehensive reviews about transder-
mal prodrug delivery, but this usually appears as a minor 
subject in broadly based articles on prodrugs. 
One transdermal delivery review incorporated codrugs 50 
and prodrugs (Strasinger et al., 2008). Prodrugs specifically 
to be used with microneedle-enhanced transdermal delivery 
are also not readily available in the literature yet (Milewski 
et al., 201 Oa; Milewski et al., 201 Ob). After three decades of 
transdermal prodrug/codrug delivery study, the field still 55 
seems relatively young with relatively small amounts of 
literature published in the area, and no products on the 
market. Synthesizing specific codrugs with varying physi-
cochemical properties and systematically studying how the 
transport and bioconversion of these codrugs are affected by 60 
these physicochemical properties will give us a greater 
database of transdermal codrug knowledge. Publication of 
the results of these carefully controlled in vitro and in vivo 
diffusion experiments with corresponding statistical rela-
tionships to physicochemical codrug properties (QSPR) will 65 
greatly add to the prodrug/codrug literature. The ability to 
choose the design of a successful prodrug/codrug based on 
16 
simple calculated and experimentally measured parameters 
could save the pharmaceutical chemist valuable time and 
effort. 
With skillful formulation and addition of skin penetration 
enhancers, some borderline delivery candidates can be made 
into transdermally useful therapeutic agents. Penetration 
enhancers are chemicals that alter the structure of the 
stratum corneum temporarily in order to open up a pathway 
for faster diffusion of drugs through skin. A major disad-
vantage to penetration enhancer use in transdermal delivery 
systems is the potential for skin irritation and allergic 
reaction. Skin irritation is a very common reason why many 
topical and transdermal dosage forms do not make it to the 
market. A major advantage of using transdermal prodrugs/ 
codrugs with prompt bio-activation is that their skin irrita-
tion and allergenic potential should only mirror the profile of 
the parent drug(s), without the possible added toxicities of 
penetration enhancers. 
Successful delivery of NTX has been shown in humans 
using microneedle enhancement for two to three days (Wer-
meling et al., 2008). Use of microneedles with optimized 
codrugs will enable naltrexone delivery rates to increase 
multiple-fold over passive delivery patches, without irritat-
ing enhancers, and with the added advantage of improving 
the delivery duration from one patch to 7 days, the optimal 
transdermal dosing goal. 
Therapeutic Goal: From the standpoint of making NTX 
transdermally useful, the present inventors contemplated a 
need for a temporary form of NTX with optimized proper-
ties to substantially increase its flux (from 3 nmol/cm2/hr to 
about 12-90 nmol/cm2/hr). The most recent depot injection 
clinical trial for alcohol dependence indicates that the 
required flux would be 34-68 nmol/cm2/hr from a 20 cm2 
patch (Garbutt et al., 2005). If the patch size is doubled, the 
required flux rate would be reduced by one half. With 
microneedle treatment alone, the present inventors found 
that NTX could be delivered at the lower end of the 
therapeutic range for opiate receptor blockade in humans, 2 
ng/mL (Verebey et al., 1976). 
The main therapeutic goal is to achieve a substantial 
increase in the flux of the codrug across the skin to reach 
effective levels in the body. This codrug would also supply 
an equimolar dose exposure to diclofenac (or other future 
COX inhibitors of choice). The minimum daily effective 
systemic therapeutic dose of diclofenac is 75 mgx0.55 oral 
bioavailability (Micromedex 1.0), or 41 mg per day. This 
translates to a required systemic delivery rate of 270 nmol/ 
cm2/hr from a 20 cm2 patch, which is several-fold higher 
than the required systemic NTX flux. 
Therefore, since the required NTX flux is the target for 
systemic therapy, the diclofenac absorbed would be sub-
therapeutic because its use in the codrug is only to deposit 
into the skin and maintain the pore lifetime through a 
localized effect. As diclofenac is a potent COX inhibitor, 
many other COX inhibitors could be used that would have 
a local effect and very little systemic effect. 
6-~-Naltrexol (NTXOL) is the major metabolite formed 
by rapid reduction ofNTX in humans (Cone et al., 197 4) and 
in several other animal species, including guinea pigs 
(Valiveti et al. 2004). NTXOL may contribute to the thera-
peutic action ofNTX in drug and alcohol dependence due to 
its significant plasma concentrations (Ferrari et al., 1998; 
Meyer et al., 1984; Wall et al., 1981) and longer terminal 
half life (McCaul et al., 2000a; McCaul et al., 2000b; 
Rukstalis et al., 2000; Wall et al., 1981) in humans compared 
to NTX. The NTXOL half-life ranged from 7.5 to 13 hours 
compared to 2-10 hours for NTX in these human subjects. 
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Additionally, NTXOL exerted a 4-9 times longer duration of 
action than NTX in different animal model experiments 
involving rats and mice. NTXOL is also an opioid antagonist 
with a similar affinity for the opioid receptors but with a 
lower potency than NTX in in vivo studies. However, the 
lower potency can be expected to be compensated by the 
presence of a much higher plasma concentration, suggesting 
that NTXOL might contribute a major role in the efficacy of 
NTX. 
18 
codrugs have been proposed for use in connection with 
microneedle systems heretofore. In order to obtain the 
fastest drug delivery rates possible, optimization of codrug 
solubility, hydrogen bonding, and bioconversion rates will 
need to be completed. 
In order to increase understanding of the QSPRs for 
transdermal codrug flux and concurrent bioconversion, one 
should start with the basics. The original 3-alkyl-ester, 
carbonate, and carbamate prodrug series for passive trans-
Recent studies have provided evidence that NTXOL may 
be of future relevance with respect to treatment of alcoholics 
as well. A preclinical study by Stromberg et al. showed that 
when given alone, NTXOL reduced alcohol consumption in 
rats in a dose-dependent manner. This was also confirmed in 
a second study (McCaul et al., 2000a; McCaul et al., 2000b ). 
In addition, serum concentrations of NTXOL have been 
shown to be associated with reductions in number of drinks 
per month (O'Malley et al., 1992) and with potentially 
important negative subjective effects of alcohol in humans 
(McCaul et al., 2000a; McCaul et al., 2000b ). In a random-
ized, double-blind clinical trial of NTX, subjects with a 
NTXOL level of more than 40 ng/ml did not experience an 
alcohol relapse (O'Malley et al. 1992), indicating that the 
relapse rate might be lower in patients treated with NTXOL. 
10 dermal permeation served as the first building block in the 
design of better prodrugs (Pillai et al., 2004; Stinchcomb et 
al., 2002; Vaddi et al., 2009; Vaddi et al., 2005). This newly 
proposed microneedle-enhancement project provides a vali-
dated methodology of studying the effects of a simple and 
15 relatively stable skin esterase enzyme system on di-conju-
gation of the NTX molecule, to determine if significant 
enhancement is achieved over and above the enhancement 
seen with the mono-conjugated codrugs of NTX. The pre-
cise balance among lipophilicity, hydrophilicity, and meta-
20 bolic bioconversion needs to be found for these codrugs, in 
order to maximize NTX flux rates across the skin and 
In addition, since NTXOL is mainly excreted through the 25 
renal route, it would be a safer alternative than NTX in 
hepato-compromised patients. All this indicates that 
NTXOL would be a useful therapy in drug addiction and 
alcoholism. Thus, the present inventors contemplate ana-
logues of NTXOL for transdermal delivery, and consider- 30 
ation of the present inventors' codrug designs with NTXOL, 
to see if significant flux enhancement for this promising drug 
can be achieved (Paudel et al., 2005). 
Microneedle Enhancement: Microneedle delivery is in its 
infancy stages of development for transdermal drug deliv- 35 
ery, but the microelectromechanical systems (MEMS) class 
that microneedles stemmed from is a multibillion dollar 
market (McAllister et al., 2003). While microneedle inser-
tion for transdermal drug delivery is new, it has shown 
promising results that show increased drug permeation; it is 40 
also a relatively painless drug delivery procedure (Kaushik 
et al., 2001). There are currently many other devices on the 
market, such as the ImplaJect™, Luer-Jet™, Iject® and 
Mini-Ject™, to deliver therapeutics systemically by needle-
free injection. The overriding problems associated with 45 
these models are that they are costly to produce, require 
medical supervision for application, and importantly are not 
pain-free (Furness). 
The microneedle would, on the other hand, cost much less 
to produce and purchase, require no office visit for applica- 50 
tion, and would be pain-free. Initial studies with 
microneedles have shown significant increases in the per-
meation oflarge molecules such as insulin (McAllister et al., 
2003). The design of the microneedle is based on the 
composition of skin, because it must pass through the 55 
stratum corneum (10-15 µm) and into viable epidermis or 
dermal layers. In theory, the microneedle must only be long 
enough to pass through the first 15 µm of skin, but most 
microneedles are significantly longer. It is pertinent that a 
microneedle works to produce a significant aqueous channel 60 
through the epidermis so that continual drug delivery 
through this channel can occur before reversal (channel 
closing) is observed. 
Examples of microneedle systems include BioValve's 
Micro-Trans™ microneedle array patch and 3M's Micro- 65 
structured Transdermal Systems (MTS). Several 
microneedle systems are in late-stage clinical trials. No 
optimize COX inhibitor deposition into the skin simultane-
ously. Different polar and/or hydrophilic codrugs with vary-
ing properties will be especially suitable for the microneedle 
flux optimization (Banks et al., 2010; Banks et al., 2008), as 
diverse prodrug forms are known to significantly change 
absorption rates of injectable drugs, if one considers 
microneedle delivery to be a micro-injection. 
There are currently no transdermal prodrug, codrug (mu-
tual prodrug), or microneedle products on the market. The 
present inventors contemplate the following innovative fea-
tures in connection with embodiments of the presently-
disclosed subject matter. 
Microneedles--carefully controlled models for transder-
mal delivery candidate selection, formulation, and 
micropore lifetime optimization will be evaluated using the 
"poke and patch" technique for systemic drug delivery. Most 
prior research in microneedle-assisted transdermal delivery 
has been for vaccines, biodegradable microneedles or coat-
ings for very potent drugs, or in optimization of needle 
engineering. Currently, the present inventors' human 
microneedle NTX pharmacokinetic study is the only pub-
lished report in this area using the "poke and patch" tech-
nique (Prausnitz and Langer, 2008; Wermeling et al., 2008). 
There is also an ongoing clinical trial for microneedle-
assisted delivery of parathyroid hormone and a human proof 
of concept study for insulin delivery using hollow 
microneedles (Prausnitz and Langer, 2008). 
Transdermal codrugs--carefully controlled design, syn-
thesis and optimization of codrug structures based on chemi-
cal stability, enzymatic stability, and solubility. Few 
examples exist in the literature concerning optimization and 
utility of transdermal codrugs (Cynkowski et al., 2008; 
Kiptoo et al., 2006; Kiptoo et al., 2008; Strasinger et al., 
2008). 
Micropore lifetime-carefully optimized pharmacoki-
netic evaluation of micropore lifetime in order to further 
evaluate the effect of diclofenac and potentially other COX 
inhibitors. Previous studies on micropore lifetime have used 
many other visualization evaluation techniques (Kalluri and 
Banga, 2009), but only a few have examined pharmacoki-
netic analysis (Banks et al., 201 O; Banks et al., 2011 ). 
Pharmacokinetic evaluation of micropore lifetime is the 
most useful and realistic applied method of evaluation. 
Drugs that are targets for microneedle-assisted delivery 
could impede or enhance the micropore closure rate, 
depending on their mechanisms of action. Additionally, very 
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few reports occur in the literature describing ways to delay 
the micropore closure, so this in itself is an extremely unique 
aspect of this project (Banks et al., 2011; Milewski et al., 
2010a). 
20 
microneedle enhancement, as compounds as large as insulin 
have been delivered through micropores (McAllister et al., 
2003). However, the present inventors have learned that an 
increase in viscosity, roughly correlated with the molecular 
weight of a compound, can decrease the diffusion rate 
through the microneedle pores (Milewski et al., 2010a; 
Milewski and Stinchcomb, 201 O; Milewski and Stinchcomb, 
2011; Milewski et al., 201 Ob), therefore polyethylene glycol 
(PEG, 11, 12) units will not be increased to over six. Codrug 
design can be limited to smaller molecular weights, if the 
solubility increase does not overshadow the molecular 
weight dependency with microneedle delivery. 
The addition of the synthesis of the di-conjugated codrugs 
Transdermal codrugs specifically for microneedle-as-
sisted delivery-the overall goal of the project is something 
that has never been done before. The present inventors' 
research has shown some of the important aspects of what 
type of prodrug/drug is best for microneedle-assisted trans-
dermal delivery (Banks et al., 2010; Banks et al., 2008; 10 
Milewski et al., 201 Oa; Milewski and Stinchcomb, 201 O; 
Milewski and Stinchcomb, 2011; Milewski et al., 201 Ob), 
but the addition of the codrug that can have optimized 
delivery rates as well as duration is very new in drug 
delivery research. 
Development of an improved 7-day transdermal system 
for NTX-this would improve patient compliance and the 
side-effect profile, as the depot injection and tablet have 
many drawbacks. The translational goal of the research is to 
develop an improved dosage form for naltrexone delivery 20 
for addicts and alcoholics. After the proof-of-concept 
research is complete, preclinical toxicology tests could be 
completed, an IND filed, and a Phase I clinical trial could 
begin at the end of three years. By this time, other 
microneedle systems should be on the market, so the pri- 25 
mary regulatory hurdle would be the safety and efficacy of 
the codrug itself. Seven day transdermal patches on the 
market are very popular products. 
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and their comparison with the successful mono-conjugated 
codrug moieties is novel. Ester, carbamate, and carbonate 
ester linked prodrugs are successful prodrugs, so these 
linkages have been maintained. All of the codrug structures 
Exemplary Compounds. 
Synthesis and testing of the compounds of FIGS. 2A and 30 
2B is now described, and contemplated with regard to other 
compounds in FIG. 2. The detailed synthetic methods are in 
the Synthetic Schemes provided hereinbelow. These two 
compounds have an ester linking naltrexone or naltrexol to 
diclofenac. The chemical stability half-life of Compound 2A 35 
in buffer (skin pH 5.0 and skin surface temperature 32° C.) 
was around 4.3 days and the enzymatic stability half-life in 
the hairless guinea pig plasma was around 6 minutes, 
indicating that any intact codrug that reached systemic 
circulation would regenerate the parent drugs as soon as it 40 
enters the body. 
In both stability studies, regeneration of the parent com-
pounds was observed with the degradation of the codrug. 
Compound 2A bioconverted completely in the skin to form 
only the parent compounds in the receiver and plasma in the 45 
in vitro diffusion and in vivo studies, respectively. Com-
pound 2A made a very good proof-of-concept drug to test in 
vitro and in vivo in order to see if sufficient diclofenac could 
be deposited into the skin for therapeutic micropore closure 
delay, and also to see if it cleaved in the skin to the parent 50 
compounds. Compound 2B was synthesized next, as the 
ester linkage to NTXOL at the 6-0 position has been found 
to be more chemically stable than linkage at the 3-0 position 
of the phenolic ring. This is another reason to use NTXOL, 
because the 6-0 position in NTX is a ketone and not a 55 
hydroxyl that can be easily made into a prodrug. However, 
other structures have been proposed to help improve the 
chemical stability of the 3-0 phenolic hydroxyl prodrug 
linkage, e.g. Compound 2C with the addition of carbons in 
between to help slow the hydrolysis, and Compound 2G and 60 
Compound 21 with carbamate and carbonate linkages. 
Experimental Design The detailed synthetic are set forth 
hereinbelow. All the reactions utilize established reagents 
and protecting chemistries. Hydrogen bonding capacity will 
be especially important in the design of the codrugs to be 65 
used with the aqueous pores formed by the microneedles. 
Molecular size can be somewhat increased in the case of the 
will be optimized to solubilize and permeate through the 
aqueous channels created by microneedle delivery. These 
microneedle-assisted codrugs will therefore be very hydro-
philic, but it is certain that a relatively fast bioconversion 
rate will still be an important property of these codrugs so 
that the diclofenac can be deposited into the skin. A more 
hydrophilic NTX codrug should more readily enter the 
microneedle-created pore, and then diffuse to the capillaries 
for systemic circulation uptake. More hydrophilic com-
pounds should be taken up by the circulation more readily 
than lipophilic compounds, as can be seen in the sustained-
release injectables body of literature, where changes in 
absorption rate correlate with lipophilicity and bioconver-
sion. For example, furanose sugar (17), L-malic acid (18, 
20), and phosphate acetic acid ester (15, 16, 19) promoieties 
will be studied to determine the flux enhancement with 
microneedles. 
If the phosphate acetic acid ester is too chemically 
unstable, a regular phosphate ester group can be substituted, 
and sodium salts of these could also be made. Salts of all of 
the compounds are contemplated, as the present inventors 
have found that this is the best form to afford an increase in 
polarity and aqueous solubility (Banks et al., 2008). The 
preferred initial salt form is hydrochloride (Scheme 1 ), but 
lactate and glycolate salts would also be good candidates, for 
example. Lactate and glyco late salts are common in topical 
preparations at high concentrations. Acetate salts would not 
be practical because of potential odor. The acetate, lactate, 
and glyco late salts have higher solubilities in the pH range 
of interest for topical application, pH 4-6. Higher flux has 
been seen from NTX glycolate than NTX HCl through 
microneedle-treated skin in vitro, because one can achieve a 
higher solubility with glyco late. There is a maximum effect 
of solubility on flux when the viscosity outweighs the 
solubility effect (Milewski and Stinchcomb, 2011). 
The goal is to categorize how the physicochemical prop-
erties of these codrug moieties when conjugated at the C-3 
phenolic hydroxyl group or at the C-6 (naltrexol) influence 
stability and flux measurements, and then to evaluate any 
trends that may become evident from physicochemical prop-
erties and flux enhancement. Otherwise, physicochemical 
properties are altered only by the codrug link in between the 
two drugs via pegylation (11, 12), or by changing the 
chemical and enzymatic stability with ester, carbonate, car-
bamate (1-10), and anhydride (13, 14) groups. The addition 
of one to four carbon atoms (3-10, 13,14) in between the 
ester, carbonate, carbamate, and anhydride linkages is pro-
posed to help improve chemical stability if necessary. Other 
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design permutations, besides the 20+ proposed basic struc-
tures, are possible once data is gathered and optimization of 
flux and stability begins. 
22 
can also be determined in skin homogenates, to ascertain if 
the values are useful in the QSPR multiple regression 
analysis. The kinetics of codrug enzymatic degradation in 
skin homogenates will be done using abdominal plastic 
surgery samples. Enzymatic reaction rates will be deter-
mined at several different codrug concentrations. The skin is 
homogenized (Polytron tissue homogenizer and ground 
glass homogenizer fitted with a glass pestle) in HEPES-
buffered Hanks' balanced salt solution and the supernatant is 
10 obtained. The enzymatic hydrolysis rates are determined in 
the homogenate at 37° C. The codrug and its metabolites 
will be obtained by solid-phase extraction, or another appro-
priate extraction method. Naltrexone and any other metabo-
lite formed will be assayed by HPLC and expressed as moles 
A goal is to optimize solubility characteristics, chemical 
stability, and bioconversion rates, the most critical prodrug 
parameters identified. With these physicochemical attributes 
maximized, a therapeutic transdermal drug delivery rate 
may be achieved (FIG. 4). The maximum metabolic trans-
formation rate may be limited at a Michaelis-Menten maxi-
mum rate, or Vmax, providing the enzymatically labile 
codrug is chemically stable enough to cross the micropores 
intact. Altering the linkages in the codrugs for polarity and 
bioconversion should significantly enhance the transdermal 
drug delivery rate. The general codrug design and synthesis 
methodology will allow for this flexibility. Many codrugs 
are proposed, but data collection will drive the decisions for 
which groups of compounds that will/will not be synthesized 
and tested, similar to what we have done with the currently 
funded proposal. In four years a maximum of 100 com-
pounds could be synthesized. This number of compounds is 20 
well within the capabilities of our synthetic chemistry exper-
tise, as we have already demonstrated in our currently 
funded studies. 
15 of metabolite per minute per milligram of protein. Protein 
concentrations in the supernatant will be measured by the 
Bradford method. Controls containing only codrug and 
HEPES-buffered Hanks' balanced salt solution at 37° C. will 
also be monitored to determine non-enzymatic hydrolysis. 
The kinetics of codrug enzymatic degradation in skin 
homogenates will also be carried out using freshly der-
matomed guinea pig skin samples. Immediately after the 
animals are euthanized, at the completion of their pharma-
cokinetic studies, untreated dorsal skin will be harvested for Calculated codrug physicochemical parameters will 
include: molecular weight and volume (Bondi), octanol/ 
water partition coefficients (Daylight® 4.51 Software), 
hydrogen-bonding potentials, relative thermodynamic activ-
ity and solubility parameters (Stinchcomb et al., 1995). A 
wide range of partition coefficients will provide a sufficient 
group of data for QSPR analysis. With every carbon addition 
to the alkyl chain, the clogP value usually increases by about 
0.5. Generally, the greater a drug's innate tendencies to 
dissolve, the more likely it is that the drug can be delivered 
at an adequate rate across any membrane, including the skin. 
Therefore, experimentally determined prodrug physico-
chemical parameters will include: octanol/water partition 
coefficients, melting points and heats of fusion (important 
physicochemical determinants of solubility), and solubilities 
in select solvents at 32° C. (buffer and other vehicles used 
25 homogenate metabolism and in vitro diffusion studies. 
These metabolism studies will help to quantify any signifi-
cant differences in the codrug enzymatic reaction rates 
between the guinea pig skin and human skin. Additionally, 
codrugs may metabolize to other compounds, besides just 
30 the parent drugs. The same procedure can also be done for 
pig skin. 
Cox inhibitors other than diclofenac are contemplated. In 
some cases, a COXl-specific inhibitor may be better, in 
which case SC560, valeryl salicylate, mofezolac, FR122047 
35 or another COXl-specific inhibitor can be used. In some 
cases, a COX2-specific inhibitor may be better, in which 
case, celecoxib, for example, can be used. In some cases, a 
less potent nonspecific COX inhibitor could be used, in 
which case ibuprofen, ketoprofen, or others are available. 
40 Such COX inhibitors have carboxylic acid moieties, and 
chemistry for synthesis does not change substantially. Cele-
coxib is an exception with an amine functional group, so 
different chemistry would be needed (Schemes), as would be 
in the permeation experiments). Skin surface temperature is 
approximately 32° C. Difficulties sometimes arise in deter-
mining the octanol/water partition coefficients of readily 
hydrolyzed esters or extremely hydrophobic drugs. Experi-
mentally determined octanol/water partition coefficients for 
some of the codrugs may not be practical, therefore relative 45 
HPLC retention times could substitute for partitioning esti-
recognized by one of ordinary skill in the art. 
Drug penetration, concurrent bioconversion, and COX 
inhibitor deposition in skin in vitro with microneedle use. 
mation. 
Solubility studies are carried out by equilibrating large 
excesses of each drug with the solvent studied. The experi-
ments will be done at skin surface temperature (32° C.). To 
hasten the attainment of equilibrium, each slurry will be 
continuously shaken or stirred. Samples will be taken, 
filtered with an appropriate filter for the solvent, measured 
with respect to volume, and either assayed directly by HPLC 
or evaporated to dryness and reconstituted for assay. Binding 
of the compounds to the filter will be checked to eliminate 
the possibility of drug adsorption on the filter and/or filter 
casing. All toxic solvents and other chemicals will be 
handled with caution, and fume hoods will be used when 
appropriate. 
The chemical stability of the prodrugs to hydrolysis and 
solvolysis at the appropriate temperatures will be deter-
mined by measuring concentrations over time in the buffers 
and solvents used in the solubility and diffusion studies. 
Chemical degradation rate constants will be important in 
distinguishing enzymatic degradation from non-enzymatic 
degradation. Codrug enzymatic metabolism rate constants 
Compound 2A was tested in the in vitro diffusion study 
using Yucatan miniature pig skin with microneedle treat-
ment. A study was conducted with Compound 2A, and a 
50 study was conducted with its HCl salt. FIG. 6 shows the skin 
concentrations obtained at different time points. NTX and 
diclofenac build to steady-state concentrations as the codrug 
hydrolyzes. More diclofenac is retained in the skin because 
it is more hydrophobic than NTX, and therefore diclofenac 
55 skin levels are higher than NTX as NTX diffuses into the 
receiver compartment. 
FIG. 5 shows a diclofenac effective skin concentration 
goal, and Compound 2A did not provide that level, however, 
the codrug was successful in the hairless guinea pig phar-
60 macokinetic study at keeping open the pores for 7 days, so 
it was most likely that more Solaraze ( diclofenac) was being 
applied than necessary in the initial guinea pig study (FIG. 
7). Therefore, a diclofenac skin concentration goal of 0.1 
µmol/g of tissue may be all that is needed for effect. At any 
65 rate, the codrug is working as designed, to allow flux of 
NTX and retain diclofenac to have an effect on the 
micropore closure rate. The present inventors are testing the 
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effect of Solaraze ( diclofenac) on the micropore closure rate 
in human volunteers, and have seen similar results. 
FIG. 6 also shows the substantial NTX flux improvement 
obtained from the compound salt as compared to the com-
pound free base, consistent with previous data (Banks et al., 
2008). Therefore, the focus will be on codrug salt forms, but 
non-salt forms are contemplated as well. This codrug com-
pletely hydrolyzed in the skin and only NTX and diclofenac 
were detected in the receiver compartment of the in vitro 
diffusion study. 
Full thickness Yucatan miniature pig skin in vitro studies 
to measure diffusion and bioconversion will provide the 
most accurate absorption data with microneedle (MN) treat-
ment. It is not necessary to use human skin when using 
microneedles, since the pig skin is the same thickness and 
the primary route of diffusion is through the MN pores and 
not the stratum corneum lipid bilayers. Human skin can be 
used in final experiments in order to make sure bioconver-
sion is similar, however, the present inventors are primarily 
taking advantage of esterase activity and have not seen a 
difference in skin metabolism for this enzyme system in 
humans vs. pigs. Pig skin is purchased from Sinclair, or 
dermatome from sacrificed pigs used in the pharmacokinetic 
studies once the skin has returned to normal. The human skin 
in these experiments will be healthy full-thickness (subcu-
taneous fat removed) abdominal plastic surgery samples 
obtained from the Cooperative Human Tissue Network 
(CHTN). Universal Precautions (OSHA standards) will be 
used when handling the human skin samples, in order to 
protect the researcher from any potential harm. IRB 
approval is not required by NIH to use non-identified 
surgical waste tissue. Microneedle arrays purchased from 
1 Ox Technology or another manufacturer will be used for all 
studies, see letter of support attached. 
Guinea pig skin samples will also be used in some in vitro 
diffusion and metabolism studies. We want to compare the 
transdermal flux rates seen in the animal in vivo data with 
animal in vitro data. It will also be important to see the 
differences between in vitro guinea pig skin and in vitro 
human/pig skin diffusion data. Since we are attempting to 
validate our in vitro human skin diffusion data with an in 
vivo animal model, we need to know the basic magnitude of 
difference in the skin permeabilities among the 3 species, if 
any. Micropore closing will not take place in vitro, so these 
experiments are used for flux optimization only. Detailed 
procedures for diffusion studies are in the publications in the 
Appendix and in our other publications. Simple analysis of 
variance (ANOVA) will determine significant differences 
among the codrugs' flux values. 
In some studies it is contemplated to increase the 
microneedle array area (and needle number), which can 
increase flux, as there is a direct increase in flux with number 
of micropores. In some cases a 1 cm2 (50 needles) array is 
used, but in other cases a 10 cm2 array, and potentially an 
even larger array could be designed. Since the therapeutic 
delivery rate in humans with NTX HCl and 400 micropores 
has been achieved, it is believed that achievement of a 7-day 
codrug therapeutic flux is highly likely as long as a solubility 
similar to NTX HCl is achieved (FIG. 4). Some chemical 
stability issues can be resolved by limiting the water in the 
final patch formulation that would be used in a microneedle 
product. 
Characterization of the Pharmacokinetics of the Drugs in 
Guinea Pigs and Yucatan Miniature Pigs In Vivo with 
Microneedle Use. 
A study was done in hairless guinea pigs using diclofenac 
(Solaraze) gel applied daily to the micropores with a reser-
24 
voir ofNTX gel on top. NTX plasma profiles after one-time 
application of MN's in hairless guinea pigs with one-time 
application of0.5 g of 16% NTX.HCl (control) compared to 
daily application of 0.5 g of 16% NTX.HCl and approxi-
mately 100 µl of Solaraze® topical gel (3% Diclofenac 
sodium), 6.7 cm2 area (n=4) are shown in FIG. 7. Micropore 
lifetime was extended up to 7 days in the presence of 
diclofenac, but NTX without diclofenac had complete 
micropore closure in a similar timeframe to the human study, 
10 2-3 days ((Banks et al., 2011) Appendix). 
Compound 2A in its HCl salt form was used to treat 4 
hairless guinea pigs. Since flux from this codrug was low, 
four patches were placed on the guinea pigs with 7% 
15 
saturated codrug gel after a single pretreatment with 
microneedles on Day 1. Microneedle treatment at each patch 
site contained 100 micropores created by a 1 cm2 50 needle 
stainless steel array rotated 90° and inserted twice. A new gel 
patch was applied at 3.5 days, as the chemical stability of 
20 Compound 2A is not ideal. Plasma samples were obtained 
from a jugular catheter over seven days and analyzed for 
drug concentration by LC/MS (Methods). In three out of the 
four guinea pigs significant NTX plasma levels were seen 
for 7 days, and the pores in one guinea pig closed at 6 days. 
25 Micropores were visualized on the skin of the animals at 7 
days by staining the skin with India ink, and the 100 pores 
can be seen clearly, including the pattern from the 90° 
rotation and re-insertion FIG. 9. Intact codrug was not 
detected in the plasma samples. Significant micropore stain-
30 ing was also seen at days 1, 4, 5, 6, and 7. 
A goal is to quantitatively characterize the transdermal 
delivery of selected naltrexone codrugs in vivo using phar-
macokinetic determinants. This will be accomplished by 
35 
comparing the kinetic profiles and parameters of intravenous 
bolus and topical applications of codrugs using the chroni-
cally annulated hairless guinea pig model. Hairless guinea 
pigs are a typical animal model used for transdermal deliv-
ery experiments. More importantly, guinea pigs have been 
40 shown to have a metabolic profile more similar to humans 
than rats or rabbits. Fifteen of the most promising codrug 
candidates screened in the in vitro experiments will be fully 
characterized in the guinea pig model. Plasma samples will 
be analyzed by LC/MS. Detailed procedures for hairless 
45 guinea pig pharmacokinetic studies and data analysis are in 
the Appendix publications and many previous publications 
from our group (Valiveti et al., 2005a; Valiveti et al., 2005b ). 
Five to six animals (guinea pigs and pigs) per treatment 
group will be used, and dosing can be done in a crossover 
50 fashion, 2 routes of administration, intravenous vs. percu-
taneous. A codrug will be considered successful if it can 
deliver a similar or greater flux than that achieved in the 
human study with NTX HCl (Wermeling et al., 2008). Four 
of the most promising codrug candidates screened in the 
55 hairless guinea pigs will be examined in the Yucatan min-
iature pig, as the thickness of the skin is more similar to 
humans, important for microneedle application. This dose-
finding proof-of-concept study in the pigs will provide data 
that can be included in an IND (Investigational New Drug) 
60 application, and optimizing the dosing of the best codrugs 
will help to prepare for pig toxicology studies required for 
the IND. ANOVA statistical analysis will be used in order to 
determine statistical significance among treatment groups. 
Skin infection is not a concern with microneedle treat-
65 ment and has not been a problem in the animal or human 
studies. Skin is swabbed with alcohol prior to microneedle 
treatment and formulations can contain microbicidal addi-
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tives, like benzyl alcohol used in our human study (Wer-
meling et al., 2008). Microneedles are also very sturdy and 
do not break in the skin. 
26 
shipping to the University of Kentucky. Pigs will be trans-
ported and acclimated for 7 days once at the university 
before initiation of any pharmacokinetic studies. Miniature 
pigs (n=5-6 per test compound) are used typically as a large 
animal model for topical/transdermal studies. This breed of 
pig is ideal for topical/transdermal studies due to minimal 
body hair compared to other breeds. The pig will be placed 
in a sling for dosing and sampling. Pigs will be dosed with 
topical drug doses after MN application and blood sampling 
LC-MS/NIS conditions: Chromatography colunm used 
was Waters Atlantis Hilic Silica 5 µm, 2.lx150withamobile 5 
phase consisting of acetonitrile:buffer 80:20 (v/v). The aque-
ous buffer consisted of 1 mM ammonium acetate with 0.1 % 
acetic acid and 5% MeOH. The injection volume was 20 µ!. 
Liquid chromatography was carried out in the isocratic 
mode at flow rate 0.3 ml/min with a total run time of 14 min. 
The retention times for NDC, NTX, NTXol, DIC and NAL 
were as follows: 6.7 min, 9.6 min, 11.4 min, 7.4 min, and 1.6 
min, respectively. 
10 
(24 pre-determined time points) will be done for up to 168 
hours. A jacket (Lomir Biomedical Inc) is placed on the pig 
to prevent the pig from removing the patches. Lidocaine 
(4%) cream is applied to the port area for 10 min prior to 
blood collection to minimize discomfort to the pig. Special-
ized Huber needles are used for flushing and sampling to The LC-MS-MS system consisted of a HPLC Waters 
Alliance 2695 Separations Module, Waters Micromass® 
Quattro Micro™ API Tandem Mass Spectrometer. Positive 
electrospray ionization was used for detection of all com-
pounds (ESI+), except DIC was analyzed through negative 
ionization (ESI-). Multiple reaction monitoring (MRM) was 
carried out with the following parent to daughter ion tran-
sitions for Compound 2A (NDC), NTX, NTXOL, diclofenac 
(DIC) and naloxone internal standard (NAL): m/z 
619~342, m/z 342-324, m/z 344~626, m/z 293~250, and 
m/z 328~310, respectively. Capillary voltage was 3.5 kV, 
RF lens 0.3 V, source temp 130° C., desolvation temperature 
270° C. and cone voltage 29 V for NTX, NTXOL and NAL, 
15 maintain the integrity of the ports. Blood removal will not 
exceed 10% of the animal's total blood volume. Plasma 
samples are harvested and analyzed by LC/MS/MS. Weights 
are obtained prior to initiation of studies and monitored 
weekly. Animals are euthanized after completion of the 
20 experiments. 
Skin irritation in hairless guinea pigs (n=5-6 per test 
compound): Erythema from topical drug treatments can be 
quantified with a Minolta ChromaMeter (Kobayashi, 
Hosaka et al. 1997; Sutinen 2000). A colorimetric measure-
25 ment of the skin reflection is taken before and after the 
18 V for DIC and 38 V for NDC. The collision gas was 19 
eV for NTX, 10 eV for DIC and 20 eV for NDC, NTXOL 
and NAL. Nitrogen gas was used as a nebulization and 
drying gas at flow rates of 50 and 450 L/h, respectively. 30 
Calibration plots were prepared by a linear regression analy-
topical drug treatment, in order to assess skin irritation 
(Kobayashi, Hosaka et al. 1997). Trans-epidermal water loss 
(TEWL) measurements will also be taken before and after 
patch application, as a relative measure of skin damage. 
These two skin measurements are complimentary, and 
should provide a good prediction of potential treatment 
irritation (Kobayashi, Hosaka et al. 1997; Sutinen 2000). 
The irritation potential of the drugs will be evaluated by 
taking erythema and trans-epidermal water loss (TEWL) 
sis of the ratio of the drug-to-internal standard areas versus 
nominal drug concentration. Quadrupoles were set on unit 
mass resolution. Based on the peak-to-noise ratios of3:1 for 
LOD the following limits of detection were estimated: 35 
NDC<l ng/ml, NTX 3 ng/ml, NTXOL 1 ng/ml and DIC 1 
ng/ml. Based on the peak-to-noise ratios oflO: 1 for LOQ the 
following limits of quantification were estimated: NDC 3 
ng/ml, NTX 10 ng/ml, NTXOL 3 ng/ml and DIC 3 ng/ml. 
readings at the induction sites after patch removal. Erythema 
from topical drug treatments will be quantified with a 
Minolta Chromameter (Kobayashi, Hosaka et al. 1997). 
Both chromameter and TEWL reading will be taken before 
and after patch removal as a relative measure of redness and 
skin damage, respectively. Readings will be taken at 5 min 
Vertebrate Animals 
The hairless guinea pig pharmacokinetic/irritation and pig 
pharmacokinetic experiments will make use of 92 guinea 
pigs (male and female IAF hairless; from Charles River 
Laboratories); 400-450 g, 6-8 weeks old 12 Yucatan minia-
ture pigs (male and female; from Sinclair BioResources); 
-15 kg, 3 months old The proposed experiments will be 
conducted as described: 
Male and female IAF hairless guinea pigs ( 400-450 g) 
will have surgical implantations of jugular catheters (phar-
macokinetic studies). Hairless guinea pigs (n=5-6 per test 
compound) are used typically as a small animal model for 
topical/transdermal studies. After a 1-2 day recovery period, 
animals will be dosed with i.v. or topical drug doses and 
blood sampling will be done for up to 96 hours. Blood 
removal will not exceed 10% of the animal's total blood 
volume. Plasma samples are harvested and analyzed by 
LC/MS. Test compounds will be screened in the guinea pigs 
and the most successful candidates will be tested in the pig 
model. Animals are euthanized at the end of the experi-
ments. 
Male and female miniature pigs (-20 kg) will be pur-
chased with two surgically implanted subcutaneous titanium 
ports (Access Technology) from Sinclair BioResources. 
Sinclair BioResources (USDA#: 43-R-0104 and assurance 
40 and thereafter at 1, 2, 24 and 48 h, and daily throughout 
treatment. Reactions will be visually graded for erythema at 
24 and 48 h after patch removal according to a 5-point 
grading scale (0, 0.5 (±), 1, 2, 3). The grades 1, 2 and 3 
denote increasing severity of erythema with grades > 1 
45 considered positive. The "0.5 or(±)" grade will be used for 
equivocal reactions and will be considered negative. 
Responses will be evaluated by two indices, one for inci-
dence and one for severity, for both test and control animals. 
The incidence index will be determined by the number of 
50 
animals showing a response grade of 1 or greater at either 24 
or 48 h out of the total animals in the group. The severity 
index will be determined for both 24 h and 48 h response 
readings by dividing the sum total of grades in a given group 
by the total number of animals exposed. 
55 
Pharmacokinetics-Pharmacokinetic parameters will be 
determined by fitting the plasma concentration vs. time data 
(AUC) during and after drug administration by nonlinear 
least squares regression analysis, using commercially avail-
able software (SCIENTIST, Micromath, Inc. or WINNON-
60 LIN) and a multi-exponential mathematical equation, as 
follows: 
n Eq. 1 
#: A4333-01) has staff veterinarians that perform the sur- 65 
geries according to IACUC protocol (#10402). The surgi-
cally implanted pigs remain on-site for 10 days before 
C = ko ~ C1(e"tT - l)e-Att 
l=i 
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where ko is the zero-order administration rate, T is the 
administration time and C/s and A./s are fitted parameters 
describing the absorption, distribution and elimination rate 
constants. The multi-exponential model will be used to 
construct smooth curves through the data to compute AUC 
and AUMC to the last time point, and will take into 
consideration, when necessary, metabolite kinetics (Row-
land and Tozer). If the multiexponential model does not 
provide an adequate fit for the data, more complex math-
ematical models will be considered. In some cases we expect 
that the codrugs will hydrolyze so rapidly to NTX that 
elimination of NTX will not be rate-limited by the biocon-
version. The clearance of NTX should be much lower than 
the codrugs' clearance values. 
The elimination rate constant (k) will be determined from 
the terminal log-linear portions of the curves. If the codrug 
and NTX exhibit similar terminal log-linear slopes after the 
i.v. dose of codrug, then the NTX elimination is rate-limited 
by its formation. The fraction (fNTX) of an i.v. dose of 
codrug converted to naltrexone will be calculated by: 
A UC(NTX --+ PRO/V) X CLNTX 
fNTX = A UC( PRO--+ PRO/V) X CLPRO 
AUC(NTX~PROIV) refers to the area under the curve of 
the naltrexone plasma profile following an i.v. bolus of 
codrug. AUC(PRO~PROIV) refers to the area under the 
curve of the codrug plasma profile following an i.v. bolus of 
codrug. The peak plasma concentrations (Cmax) after the 
i.v. bolus doses of the drug will be used to determine the 
initial volume of distribution by the following equation: 
Dose 
V=--
Cmax 
Noncompartmental pharmacokinetic determinants calcu-
lated will be total clearance (CL=[dose]/AUC), volume of 
distribution at steady-state (Vss=dosex[AUMC/AUC2 -T/ 
(2xAUC)]), and MRT (MRT=AUMC0_jAUC0 _=-T/2). 
(AUC=Area under the concentration vs. time curve; 
AUMC=Area under the first-moment-time curve; 
MRT=Mean residence time)(Gibaldi and Perrier). The per-
cutaneous absorption data from rapidly skin-converted cod-
rugs should provide a plasma concentration time profile that 
exhibits zero-order delivery to an average steady-state level 
(Css) of parent drug. 
The average transdermal codrug absorption rate R should 
also be equal to: 
C,,Vk 
R=--
fNrx 
Where Css, V, and k are parent drug values. After removal 
of the topical codrug treatment, the elimination would be 
controlled by the compound with the longer elimination 
half-life, in some cases parent drug. Statistical analyses for 
group comparisons will be evaluated by ANOVA, followed 
by Tukey post-hoc testing for individual group differences. 
Differences will be considered significant when p<0.05. 
Changes in flux enhancement that we have seen in the in 
vitro studies should be mimicked in the in vivo studies. For 
example, if a codrug provides a two-fold increase in NTX 
28 
flux in vitro, one would expect to see the steady-state plasma 
concentrations of NTX double (see FIG. 10). 
Lag times will be calculated for each individual set of 
data. After the topical treatment is removed, the plasma 
levels will begin a first-order decline after the "drug reser-
voir" remaining in the skin is eliminated. The residual levels 
of drug left in the skin will be monitored, and an elimination 
rate constant will be calculated from the terminal log-linear 
portion of the profile. The peak plasma concentration 
10 (Cmax) and time to reach the Cmax (tmax) will be read 
directly from the plasma-concentration time profiles. 
Preliminary in vitro miniature pig skin studies have been 
completed for this project. Animal experiments are also 
contemplated. A 1997 article describing a type of artificial 
15 skin was identified. These systems have the same type of 
disadvantages as any in vitro testing: the microcirculation 
and enzymatic activity of the in vivo skin model is not 
represented. It is not possible to study irritation and phar-
macokinetics without an in vivo model. Guinea pigs have a 
20 history of use in topical irritation testing. Hairless guinea 
pigs are a typical small animal model used for transdermal 
experiments. More importantly, guinea pigs have been 
shown to have a metabolic profile more similar to humans 
than rats or rabbits. Miniature pigs are used typically as a 
25 large animal model for transdermal studies. From previous 
experience with animal studies, guinea pigs and pigs can be 
tested more than once following a washout period which 
helps to reduce the number of animals needed to complete 
the necessary studies. Animal studies are necessary to gather 
30 preliminary data in order to determine safety of the com-
pounds and pharmacokinetics before clinical studies are 
conducted. Based on experience from previous research and 
other researchers, these protocols have been established for 
the number of animals required to provide sufficient statis-
35 tical power to detect significant differences at p<0.05 using 
ANOVA and Tukey post-hoc comparisons. The number of 
animals used is in confoiinity with good pharmacological 
practices. 
The University Department of Laboratory Animal 
40 Resources (DLAR) has several full-time veterinarians avail-
able that can evaluate the animals if any infection or adverse 
reaction occurs. The University operates to comply with the 
USDAAnimal Welfare Act (Public Law 89-544) as amended 
by PL91-579 (1970) PL94-279 (1976) and 45CFR37618 
45 (6-30-80); Health Research Extension Act of 1985 (Public 
Law 99-158); follows the Public health Service Policy on 
Humane Care and Use of Laboratory Animals (revised 
September 1986); and the Guide for the Care and Use of 
Laboratory Animals DHEW (NIH) 85-23 revised 1985. The 
50 facilities' staff involved with institutional animal care and 
use is adequately trained and competent and abides by all 
provisions set forth by the Animal Welfare Act as well as 
other federal, state, and local laws for Animal Welfare. If any 
animals have infections or injury, a facility veterinarian will 
55 be consulted and the appropriate treatment will be made or 
if necessary the animal will be euthanized. The facility's 
veterinarians will be consulted to determine if administering 
of analgesics are advised or terminating the study at that 
point. The studies are not considered a painful procedure 
60 unless the procedure causes more than slightly or momen-
tary pain or distress in a human being to which the procedure 
was applied, this is pain in excess of that caused by 
injections or other minor procedures. If the test compounds 
used elicit a painful response or maximum scores, the animal 
65 will be humanely euthanized as per the University standard 
operating procedures or the animal will receive the appro-
priate sedatives, analgesics, or anesthetics as per the Uni-
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versity standard operating procedures. All surgical and tis-
sue collection procedures are conducted under general 
anesthesia. 
30 
by injections or other minor procedures. If the test com-
pounds used elicit a painful response or maximum scores, 
the animal will be humanely euthanized as per the Univer-
sity standard operating procedures or the animal will receive 
the appropriate sedatives, analgesics, or anesthetics as per 
the University standard operating procedures. All surgical 
and tissue collection procedures are conducted under general 
anesthesia. The facilities' staff involved with institutional 
animal care and use is adequately trained and competent and 
abides by all provisions set forth by the Animal Welfare Act 
as well as other federal, state, and local laws for Animal 
Welfare. 
All animals are acclimated 7 days prior to initiation of the 
studies. All animals are judged to be healthy prior to 
utilization in the study. Each guinea pig will be housed 
individually in a plastic cage with access to two water bottles 
and food. The animals will be fed a standard guinea pig diet 
daily ad libitum. Aseptic surgery will be performed on the 10 
guinea pigs. The animals will be fasted four hours prior to 
surgery. Guinea pigs will receive pre-operatively glycopy-
rolate (0.02 mg/kg, sc) and buprenorphine (0.05 mg/kg, sc). 
Guinea pigs will be anesthetized with ketamine (100 mg/kg, 
There will be no unnecessary duplication of studies and 
15 
that all reasonable efforts will be made to minimize animal 
ip) and xylazine (8 mg/kg, im). Additional ketamine and 
xylazine is administered as needed. A sterile catheter will be 
inserted into the jugular vein. All catheters will be tunneled 
to the back, secured, and plugged. Intraoperative monitoring 
exposure to pain, stress, and discomfort whenever possible. 
All protocols are approved by the University Institutional 
Animal Care and Use committee. All personnel handling 
laboratory animals are required to successfully complete a 
of the animal's condition will include respiration, heart rate, 
and response to stimulation. Post-op the guinea pigs will be 
given buprenorphine (0.4 mg/kg, sc) for analgesia and an 
antibiotic (fluoroquino lone; 5 mg/kg, sc) if infection occurs. 
Each pig will have a ten square foot pen with free access 
to fresh water. The animals will be fed a standard pig diet 
twice daily. Pigs will be restrained in a sling during blood 
sample draws from the chronically implanted catheter. If the 
pigs are kept in the sling for several hours, they will have 
access to water. Pig acclimation to the sling for several hours 
at a time will be done during the first week after the animals' 
arrival. The pigs will be monitored for undue stress from the 
restraint. For the previously described procedures, Yucatan 
miniature pigs will be momentarily restrained for procedures 
and dosing and then will be returned to their respective cages 
for observations. Lidocaine ( 4%) cream is applied to the port 
area for 10 min prior to blood collection to minimize 
discomfort to the pig. 
20 basic training program (Education and Training in the Care 
and Use of Laboratory Animals: A Guide for Developing 
Institutional Programs, National Academy Press, 1991). 
Additional species and procedure specific training programs 
are provided through the DLAR training program and the 
25 AALAS Learning Library is available to all University 
personnel using vertebrate animals in research and teaching. 
If the test compounds used elicit a painful response or if 
maximum scores, the animal will be humanely euthanized as 
per the University DLAR's standard operating procedures if 
30 the appropriate sedatives, analgesics, or anesthetics would 
not alleviate the pain or distress of the animal. If the animal 
has a weight loss of greater than 10%, the animal will be 
humanely euthanized. At the end of the experiments, guinea 
35 
pigs (minimum dosage of 0.22 mL/kg of body weight) will 
receive Beuthanasia-D Special (pentobarbital sodium and 
phenytoin sodium) overdose. At the end of the experiments, 
pigs will be sedated with ketamine (20 mg/kg, im) and 
Irritation readings in hairless guinea pigs are monitored at 
40 
5 min and thereafter at 1, 2, 24 and 48 h after application. 
Reactions will be visually graded for erythema at 24 and 48 
h after patch removal. 
Observations are made at least once daily for the remain-
der of the studies. Hairless guinea pigs and miniature pigs 45 
are monitored at each time point blood samples are obtained 
for pharmacokinetic studies and at least once daily for the 
remainder of the studies. Daily weights and rectal tempera-
tures are obtained from the guinea pigs. Biweekly weights 
50 
and rectal temperatures are obtained from the miniature pigs. 
Guinea pigs and pigs will be housed individually. All 
animals will be fed a standard diet and offered ad libitum 
water. 
For the previously described procedures, guinea pigs will 55 
be momentarily restrained for procedures and dosing and 
then will be returned to their respective cages for observa-
tions. If any animals have infections or injury, a facility 
veterinarian will be consulted and the appropriate treatment 
will be made or if necessary the animal will be euthanized. 60 
The facility's veterinarians will be consulted to determine if 
administering of analgesics are advised or terminating the 
study at that point. The studies are not considered a painful 
procedure unless the procedure causes more than slightly or 65 
momentary pain or distress in a human being to which the 
procedure was applied, this is pain in excess of that caused 
euthanized with an intravenous overdose of Beuthanasia-D 
Special as approved by theAVMA panel on Euthanasia. This 
type of euthanasia is simple and routinely used for guinea 
pigs and pigs at the animal research facilities. 
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1,4-Dioxane 
reflux 
Commercially available sodium salt of diclofenac (21) 
will be protected with Boe group using Boe anhydride to 
prevent intramolecular cyclization reaction. After overnight 
reaction at room temperature, Boe-protected diclofenac (22) 
will be obtained by extraction using diethyl ether and cold 
IN HCI. Compound 22 and naltrexone (23) will be coupled 
using conventional coupling approach to yield a Boe-pro-
32 
tected codrug. Boe-protected diclofenac-naltrexone codrug 
(I) will be dissolved in I, 4-dioxane and treated with 
equimolar 2M HCl in dioxane to give hydrochloride salt of 
diclofenac-naltrexone (24) after I h reflux. To determine 
whether acid groups can be readily attached to naltrexone or 
naltrexol, we performed a pilot experiment using Boe- or 
Fmoc-protected amino acids, successfully yielding amino 
acid-coupled naltrexone or naltrexol. 
Codrug-1: Sodium salt of diclofenac was dissolved in I: I 
(Ethyl acetate:Water) mixture and acidified with concen-
10 trated hydrochloric acid. Organic layer was separated and 
aqueous layer treated with ethyl acetate two times. Com-
bined organic layer was dried on anhydrous sodium sulfate 
and rotary evaporated to remove reaction solvents. 
Diclofenac free acid was activated with DCC (N, N'-Dicy-
clohexyl carbodiimide)) and DMAP (4-Dimethylaminopyri-
15 dine) in dry tetrahydrofuran. After two hours, equivalent 
naltrexone was added in dry tetrahydrofuran. Combined 
reactants were allowed to stir over night under nitrogen 
atmosphere. After completion of the reaction, solvents were 
removed under reduced pressure and reaction crude mixture 
20 purified by flash silica gel column chromatography eluting 
with 80% ethyl acetate and 20% cyclohexane and codrug-1 
was obtained in 56% (Scheme-I) yield. The codrug-1 was 
dissolved in I, 4-dioxane and an equimolar amount of 2M 
hydrochloric acid in dioxane was added and refluxed for 1.5 
25 hrs, and precipitated with hexanes to get hydrochloride salt 
codrug-24 (Scheme-I). 
1HNMR (CDC13 , 300 MHz): ll 6.57 (d, lH), 6.60 (d, 2H), 
6.75 (d, lH), 6.93 (m, 2H), 7.19 (t, lH), 7.29 (m, 2H) 
13CNMR(CDC13 , (300 MHz): ll 4.22, 4.41, 9.77, 23.31, 
30 31.09, 31.59, 36.45, 38.50, 43.75, 51.01, 59.48, 62.15, 
70.28, 90.93, 118.75, 119.52, 122.45, 123.05, 124.19, 
124.31, 128.30, 128.97, 129.73, 130.38, 130.64, 131.31, 
132.63, 138.09, 142.92, 147.77, 169.98, 207.67 
HRMS: Calculated for C34H320 5 N2 Cl2 618.1688 and 
found 618.1697. 
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Naltrexol (24) was synthesized with a reported process 
(Decosta, Iadarola et al. 1992) and phenolic hydroxyl group 20 
was protected with benzyl bromide to get compound (25) 
(Pelotte, Smith et al. 2009). Benzyl protected naltrexol (25) 
will be coupled with Boe-protected diclofenac acid (22) to 
provide naltrexol-diclofenac codrug-(2). This codrug on 
treatment with hydrochloric acid produced the salt form of 25 
codrug-(27). 
Codrug-2: Diclofenac acid was dissolved in dry THF and 
activated with DCC/DMAP for about two hours on an ice 
bath. Later on 3-0Bn-6-~-naltrexol was added drop wise in 
30 
dry THF, and reaction mixture allowed to stir over night 
under nitrogen atmosphere. Completion of the reaction was 
monitored with TLC and crude compound washed with 
ethyl acetate to get rid of dicyclohexy urea and purification 
on silica column gave titled compound-2 (Scheme-2) in 60% 35 
yield. 
Chemical Formula: C34H34Cl2N20 5 , Exact Mass: 620.18, 
Molecular Weight: 621.55 
1H-NMR (CDC13 , 500 MHz) ll 7.34-7.30 (m, 2H), 7.26- 40 
7.7.24 (m, lH), 7.16-7.07 (m, lH), 6.97 (s, 2H), 6.88-6.85 
0 
~~~o 
ucX) 
2 
-continued y:Cl _,..Boe 
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(m, lH), 6.70-6.68 (m, lH), 6.56 (m, lH), 4.74-4.62 (m, 
2H), 3.85 (s, 2H), 3.08 (s, lH), 3.02-2.98 (m, lH), 2.64-2.55 
(m, 2H), 2.36-2.23 (m, 3H), 2.12-2.07 (m, lH) 2.01-1.63 (m, 
lH), 1.79-1.76 (m, lH), 1.59-1.57 (m, lH), 1.46-1.40 (m, 
45 
2H), 1.25 (m, 3H), 0.87-0.83 (m, 2H), 0.83-0.51 (m, 2H), 
0.11 (s, 2H) 
MS-spec: calcd. 621.2 (M+Ht. found 621.2. 
Commercially available benzyl protected hydroxy acids 
(28) will be used in this synthesis. If not required, starting 
material will be synthesized according to reported proce-
dures (Sunazuka, Tsuzuki et al. 1992). Precursor (29) will be 
Seheme-3 
0 22 
HO II 
~OBn 
DCC 
DMAP -
28 
(YC! 
y _,..Boe 
0
' ~o~OBo UM 
29 
50 
obtained on DCC coupling ofbenzyl protected hydroxy acid 
(28) and Boc-diclofenac acid (22). Hydrogenation of com-
pound 29 followed by coupling with naltrexone (23) will 
give codrug-(3). 
55 
Seheme-4 
Cf 
Cl 
60 
_,..Boe 
N 0 
65 
0 0°00 H UM 
30 
1. 25 
DCCI 
DMAP 
2. H+ 
US 9,566,341 Bl 
35 36 
-continued -continued 
,,?' Cl BnO~: 
(I( 0 OH 
YNH 0 N~ H1/Pd-C 
c100~0 
u~ 
31 
HO 
10 
1. 22 
EDC 
2. H+ 
NC! 
YNH 0 
ClITTO ~ I ~o 
~ 0 
N~15 
-N~ 
34 
4 
20 
Parallel protocol will be used to make codrug-( 4). Deben-
zylation via hydrogenolysis of intermediate (31) will give 
rl 
Cl~Cl 
iarget codrug-( 4). 25 
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Boe protected amino acids (32) will be used to make 
codrugs-(5) and -(6) as outlined in schemes-5 and -6. Once 
Boe protected amino acid is attached to naltrexone (23) with 
45 DCC mediated coupling to get (33), Boe group will be 
removed with well-known deprotection methods. Amino 
compound (34) and naltrexone (23) will be coupled to yield 
codrug-(5). 
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To make codrug-(6) with ester and amide link, benzyl 
protected naltrexol (25) will be used. Debenzylation of (37) 
will yield codrug-(6). 
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Mono benzyl amine protected starting materials will be 
used to produce amide-amide linked spacer codrug-(7). 
Unavailable starting amino compounds will be synthesized 
according to published methods (Krivickas, Tamanini et al. 
2007). Triphosgene treated naltrexone (Hamad, Kiptoo et al. 
2006) (23) on action with (38) will give compound 39 
(Scheme 7). As outlined in scheme-7, codrug-(8) will be 
synthesized by hydrogenation of compound 39. 
40 
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0-mono benzyl protected dials ( 40) will be used as 
starting materials for the projected synthesis or materials 
25 
will be synthesized according to literature protocols (G. 
Venkateswar Reddy 2009), (Simas, Pais et al. 2003). DCC 
mediated union between diclofenac acid (22) and 0-mono 
benzyl dial ( 40) will give derivative-( 41 ). This derivative 
(41) on debenzylation gives composite ( 42) and on followed 
reaction with triphosgene treated benzyl protected naltrexol 
(Hamad, Kiptoo et al. 2006) (25) will give a new interme-
diate (43). Hydrogenolysis of (43) will give codrug-(9) 
(Scheme 8). Codrug-(10) will also be synthesized by using 
naltrexone (23) and triphosgene reagent. 
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Pegylated codrugs-(11) and -(12) are designed based on 
reported studies (Bonina, Puglia et al. 2001) and will be 
synthesized as described in scheme-9. To avoid potential 
toxicity, the peg spacers will be used from n=4. Mono 
0-benzyl PEG spacer will be synthesized with small adap-
tation per the reported protocols (Bellouard, Chuburu et al. 
~. 
~0~0Vyo~ ~ o I # o'&c' 00 OH N~ 
11 
12 
30 1999), (Jiang and Yu 2008). PEG hydroxyl acid (44) on 
DCC coupling with naltrexone (23) will give peglylated 
naltrexone compound ( 45) and on further DCC coupling 
with diclofenac acid (22) will give PEG linked codrug-(11 ). 
By using benzyl protected naltrexol (25) PEG spacer linked 
diclofenac-naltrexol codrug-(12) will be synthesized. 
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Anhydride codrugs are proposed based on research 15 
articles of diclofenac anhydride prodrugs (Mizrahi and 
Domb 2009). Mono benzyl protected dicarboxylic acids ( 47) 
will be used for synthesis of codrugs-(13) and -(14) as 
outlined in scheme-10. Debenzylation and DCC mediated 
coupling with naltrexone (23) will give codrug-(13). If 20 
starting materials are not commercially available they will 
be synthesized according to the following reference (Bal-
lard, Richards et al. 2008). Diclofenac derivative (49) on 
DCC coupling with benzyl protected naltrexol (25) will give 
intermediate (50). This compound on hydrogenolysis will 
give codrug-(14). 25 
Scheme-11 
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To increase the aqueous solubility, several codrugs are 
proposed in schemes-11-14. These codrugs are planned 
0 
~~~o uc:O 
52 
N~ 
53 
N'7 
1. 22 
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45 based on the following published research (Du, Hong et al. 
2007), (Rouquayrol, Gaucher et al. 2001), (Baba and Yosh-
ioka 2006). Water solubilizing phosphate, amino acid and 
L-malic acid moieties will be attached to phenolic hydroxy 
50 group of naltrexone (23) and aliphatic hydroxyl group of 
naltrexol (24). Naltrexol derivative in scheme-12 will be 
synthesized according to reported synthesis (Nelson, Davis 
et al. 1994). 
Scheme-12 
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Final codrugs and all intermediate compounds will be 
completely characterized by 1 HNMR, 13CNMR spectros-
copy and mass spectrometry. All the codrugs will be con-
verted to hydrochloride, glycolate and lactate salts according 
to mentioned reference (B. S. Somashekar 2005). 
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Celecoxib (60) will be reacted with different cyclic anhy-
drides to make intermediate (61), similar to some published 
protocols (Mantarosie, Coman et al. 2008), (Paun, Stere et 
al. 2008). Terminal carboxylic acid free compound (61) will 
attach to naltrexone (23) or benzyl protected naltrexol (25) 
to get target codrugs-21 and 22 (Scheme-14). 
Example 2 
The compound of FIG. 2U (Compound 2U) is studied. 
Stability: The chemical stability of the compound in the 
pH 5.0 acetate buffer (0.3M) was 3.9±0.56 days and the 
enzymatic stability in the hairless guinea pig (HGP) plasma 
was 6.4±0.84 min (n=3) indicating that the compound would 
be degraded to regenerate the parent drugs as soon as it 
enters the body. In both the studies regeneration of the 
parents was observed with the degradation of the compound. 
54 
N~ 
0 
21 
22 
0.42±0.12 nmol/(cm2/hr) (p<0.005). The skin concentration 
for both naltrexone and the compound also increased. n=4 
40 for the flux calculation. FIG. 15. So the flux increased by 
about 13 times using the salt form of the compound over the 
free base form. 
Precipitation issues were observed with purely aqueous 
donor, so an in vitro formulation development experiment 
was carried out by varying the amount of PG in the donor. 
45 10%, 25% and 50% PG was used with the salt form and it 
was observed that while there was no significant difference 
in flux between the aqueous formulation and 10% PG 
containing formulation (p<0.05), but flux decreased signifi-
cantly for higher concentrations of PG. The data was com-
50 pared using one way ANOVA and Tukey's posthoc analysis 
for pairwise multiple comparisons. The 10% PG containing 
formulation was hence chosen for in vivo studies. All 
experiments were carried out with a saturated donor solu-
tion. 
In vitro: The first in vitro experiments showed that the 55 
compound degraded in the skin to regenerate back the parent 
drugs even at 24 hours and amount of parent drugs from the 
compound increased with time. Steady state flux was 
obtained both from naltrexone and diclofenac of 0.42±0.12 
nmol/(cm2/hr) and 0.19±0.06 nmol/(cm2/hr) respectively 60 
(FIG. 14A). The naltrexone flux was significantly higher 
compared to diclofenac (p<0.05). The skin concentration 
data is shown below in FIG. 14B. n=3 for flux calculation; 
n=2 for skin concentration studies at 36 and 48 hr timepoint 
and n=3 for 12 and 24 hr. (FIG. 14B). 65 
In vivo experiments. The pores can be clearly visualized 
with gentian violet in FIG. 15 (A) immediately following 
MN treatment. In panel (B) the pores cannot be visualized 
at day 4 (96 h) pores treatment with MN followed by 
application of NTX HCl gel under occlusion. Pores can be 
visualized by India ink staining in panel C where the 
hydrochloride salt form of the compound was used follow-
ing MN treatment indicating that the pores can stay open up 
to a 7 day time point. 
The compound of FIG. 2V (Compound 2V) is studied. 
Stability A chemical stability study was done for the 
compound 2 in 0.3M acetate buffer pH 5.0 at 32° C. The half 
life was approximately 56.3±9.5 days 
The flux of naltrexone from the hydrochloride salt form of 
the compound was 5.42±1.5 nmol/(cm2/hr) compared to 
US 9,566,341 Bl 
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In vitro experiments The compound was tested in a 10% 
PG containing saturated donor formulation for in vitro flux 
and a naltrexol flux of approximately 0.29±0.09 nmol/cm2/h 
was obtained from the compound compared to 3.07±0.27 
nmol/cm2/h naltrexol flux from 10% PG containing satu-
rated naltrexol formulation. See FIG. 18. 
The compound of FIG. 2W (Compound 2W) is studied. 
A chemical stability study was done for the compound 
2W in 0.3M acetate buffer 
Chemical stability 
(days) 
Enzymatic stability 
(minutes) 
Methods: 
Compound 2A Compound 2B Compound 2C 
3.9 ± 0.56 56.3 ± 9.5 37.08 ± 1.22 
6.4 ± 0.84 min 
For all in vitro experiments female Yucatan minipig skin 
(6 months old) were used. Skin sections were obtained by 
removing the subcutaneous fatty tissue by scalpel dissection, 
and were stored at -20° C. A PermeGear flow-through 
(In-Line, Riegelsville, Pa., USA) diffusion cell system was 
used for the skin permeation studies. Skin used for 
microneedle treatment was placed on a wafer of polydim-
ethylsiloxane polymer, which mimicked the underlying 
mechanical support of tissue because of its comparable 
structural flexibility and elasticity. 
The skin was pierced 20 times with an array containing 5 
MN (i.e., to make a total of 100 individual and non-over 
lapping piercings) before mounting the skin in the diffusion 
cell for the treatment group. The insertion of MN into skin 
was carried out manually by applying gentle finger pressure 
followed by instantaneous removal. MN's were distributed 
evenly within the 0.95 cm2 area of skin and could easily be 
visualized after each 5 MN insertion, as to prevent reappli-
cation in the same area. Single MN array of 5 were used 
simply out of ease for the experimental procedure. If any 
damage to an MN section was observed the section was 
replaced. Cells containing MN treated skin showed no 
presence of receiver solution back flow into the donor 
compartment. Untreated skin samples were simply placed in 
the diffusion cells. Diffusion cells were kept at 32° C. using 
a circulating water bath. Data were collected using skin from 
a single pig 3-4 cells for the MN treated formulations. 
56 
bottom of the rubber ringed barrier to maintain mt1mate 
contact with the skin and prevent evaporation of the 300 µL 
gel formulations. 
Gel Formulations 
4% w/w gels were prepared with the hydrochloride salt 
form of the compound for in vivo studies. Hydrochloride salt 
gels were formulated by dissolving 4% compound salt in 
propylene glycol: acetate buffer at pH 4.8-10:90 and 3.0% 
hydroxyethylcellulose polymer. As the polymer was dis-
10 solved over a 30 minute period, the solution was continu-
ously stirred to ensure salvation as well as to initiate 
polymerization. The solution was stirred still a viscous gel 
resulted and then left at room temperature for 11/2 to 2 hours 
to remove bubbles and ensure complete polymerization. The 
15 gel was saturated with excess solid and therefore was a 
cloudy gel. 
Pharmacokinetic Animal Studies 
Hairless IAF guinea pigs (Charles River) weighing 350-
650 g were used for these studies. All animal studies were 
20 in accordance with the institutional guidelines and approved 
by the University of Kentucky IACUC. Surgical procedure 
was performed to canulate the jugular vein. Blood samples 
(0.3 mL) were drawn from the jugular vein at regular time 
intervals for the time studied. MN treated animals were first 
25 cleaned topically with isopropyl alcohol, and two 50 MN 
arrays were then manually applied to each dose site. For MN 
treated GPs, four 0.3 mL gel doses were applied to the dorsal 
region of the hairless guinea pigs at 4 sites to obtain steady 
state plasma levels. After application of the gel the skin was 
30 occluded with the patch and occlusive tape was applied to 
prevent evaporation of the formulation Blood samples were 
obtained for 7 days while the patch was changed with new 
formulation at 3.5 days. The blood samples were immedi-
ately centrifuged at 10,000xg for 3 min; plasma was sepa-
35 rated and stored at - 70° C. until analysis. 
Staining 
The patches were removed at predetermined time points 
and the site was cleaned with sterile gauze. Gentian violet/ 
India ink was applied as the dyeing agent at the MN treated 
40 sites and allowed to dry before excess dye was removed with 
ethanol and gauze. Both the dyes stain the viable epidermis 
but not the intact SC. Hence, a grid is observed only in the 
presence of micropores in the skin, no staining is observed 
in its absence immersing the skin pieces in ACN overnight 
45 in a water bath shaker at 32° C. The donor was removed 
from the top of the skin at the end of the study and analyzed 
by direct injection onto HPLC after suitable dilution using 
ACN. The physiological receiver solution was water adjusted to 
pH 7.4 containing 20% ethanol, and the flow rate was 
adjusted to 1.5 ml/h. Each cell was charged with 0.25 ml of 50 
the donor in the donor compartment of the chamber. The 
diffusion cells were covered with a stopper to prevent 
evaporation. Samples were collected from the receiver com-
partment in six-hour increments over 48 h or for the length 
HPLC analysis. Quantitative analysis of naltrexone, 
diclofenac and the compound concentrations in all samples 
were carried out using a HPLC assay. The receiver samples 
were concentrated 10 fold with acetonitrile by evaporating 1 
ml of the solution under nitrogen and reconstituting in 100 
µl of ACN and injected into the HPLC. The skin samples 
of the treatment. All samples were stored at 4 ° C. until 55 
analyzed by HPLC. 
The skin samples at the end of the treatment period was 
removed, the treatment area was cut out with a scalpel and 
diced into small pieces. Extraction of drug was done by The 
transdermal occlusive protective covering patches were fab- 60 
ricated by sandwiching a rubber ringed barrier to create a 
reservoir between a drug-impermeable backing membrane 
(Scotchpak™ #1109 SPAK 1.34 MIL Heat Sealable Poly-
ester Film) and anARcare® 7396 adhesive around the edge 
of the rubber spacer. The impermeable backing laminate was 65 
adhered to the rubber retaining ringed barrier with 3M™ 
double sided tape. Finally, ARcare® 7396 was placed on the 
were directly injected onto the HPLC. The HPLC system 
consisted of a Waters 717 plus autosampler, a Waters 600 
quaternary pump, and a Waters 2487 dual wavelength absor-
bance detector with Waters Empower™ software. A Brown-
lee (Wellesley, Mass., USA) C-18 reversed phase Spheri-5 
µm column (220x4.6 mm) with a C-18 reversed phase guard 
column of the same type (15x3.2 mm) by Perkin Elmer® 
was used with the UV detector set at a wavelength of 215 nm 
or 280 nm. The mobile phase consisted of 70:30 (v/v) 
ACN:(0.1 % TFA with 0.065% I-octane sulfonic acid 
sodium salt, adjusted to pH 3.0 with TEA aqueous phase). 
Samples were run at a flow rate of 1.5 ml/min with a run 
time of 8.5 min. The injection volume used was 25 µl for 
US 9,566,341 Bl 
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receiver samples and 100 µl for the skin samples. The 
retention time of naltrexone was 2.3 minutes, diclofenac was 
3.5 minutes and compound was 6.5 minutes. Samples were 
analyzed within a linear range of standard curve for all the 
three compounds from 100-10000 ng/ml. The standard solu-
tions exhibited excellent linearity over the entire concentra-
tion range employed in the assays. For the plasma samples 
the mobile phase consisted of 50:50 (v/v) ACN:(0.1 % TFA 
with 0.065% I-octane sulfonic acid sodium salt, adjusted to 
pH 3.0 with TEA aqueous phase). Samples were run at a 10 
flow rate of 1.0 ml/min with a run time of 37 minutes and 
58 
but not the intact SC. Hence, a grid is observed only in the 
presence of micropores in the skin, no staining is observed 
in its absence. 
Example 3 
Microneedle enhanced transdermal drug delivery enables 
the transport of a host of molecules that cannot be delivered 
across the skin by passive diffusion alone. However, the skin 
being a self-regenerating organ heals itself and thus prevents 
delivery of molecules across micropores for a seven day 
time period, the ideal transdermal delivery goal. Hence, it is 
necessary to employ a second drug molecule, a cyclooxy-
genase inhibitor to enhance pore lifetime by decreasing 
injection volume of 10 µ!.The retention time for naltrexone 
was 3.3 minutes, diclofenac was 16 minutes and compound 
was 33 minutes. Compound 2B and Compound 2C were 
detected using the same assay. The retention times were 5.8 
and 4.3 minutes respectively. 
In vivo experiments. Fabrication of transdermal patches 
Transdermal Patches. 
The transdermal occlusive protective covering patches 
were fabricated by sandwiching a rubber ringed barrier to 
create a reservoir between a drug-impermeable backing 
membrane (Scotchpak™ #1109 SPAK 1.34 MIL Heat Seal-
able Polyester Film) and anARcare® 7396 adhesive around 
the edge of the rubber spacer. The impermeable backing 
laminate was adhered to the rubber retaining ringed barrier 
with 3M™ double sided tape. Finally, ARcare® 7396 was 
placed on the bottom of the rubber ringed barrier to maintain 
intimate contact with the skin and prevent evaporation of the 
300 µL gel formulations. 
15 inflammatory response following microneedle treatment. A 
codrug approach using a 3-0-ester codrug of naltrexone, the 
model drug with diclofenac, a cyclooxygenase inhibitor was 
tested in vitro as well as in vivo to look at stability, 
bioconversion as well as permeation. The results indicate 
20 that the approach could be useful for transdermal drug 
delivery of naltrexone from a single patch for a week, but 
stability and solubility enhancement will be required before 
it can deliver therapeutically relevant levels of the drug. The 
skin concentration of diclofenac was high enough to keep 
25 the pores open in vivo in a hairless guinea pig model as 
evidenced by pore visualization studies. 
Gel Formulations 30 
4% w/w gels were prepared with the hydrochloride salt 
form of the compound for in vivo studies. Hydrochloride salt 
gels were formulated by dissolving 4% compound salt in 
propylene glycol: acetate buffer at pH 4.8-10:90 and 3.0% 
hydroxyethylcellulose polymer. As the polymer was dis- 35 
solved over a 30 minute period, the solution was continu-
ously stirred to ensure salvation as well as to initiate 
polymerization. The solution was stirred still a viscous gel 
resulted and then left at room temperature for 11/2 to 2 hours 
to remove bubbles and ensure complete polymerization. The 40 
gel was saturated with excess solid and therefore was a 
cloudy gel. 
Pharmacokinetic Animal Studies 
Hairless IAF guinea pigs (Charles River) weighing 350-
650 g were used for these studies. All animal studies were 45 
in accordance with the institutional guidelines and approved 
by the University of Kentucky IACUC. Surgical procedure 
was performed to canulate the jugular vein. Blood samples 
(0.3 mL) were drawn from the jugular vein at regular time 
intervals for the time studied. MN treated animals were first 50 
cleaned topically with isopropyl alcohol, and two 50 MN 
arrays were then manually applied to each dose site. For MN 
treated GPs, four 0.3 mL gel doses were applied to the dorsal 
region of the hairless guinea pigs at 4 sites to obtain steady 
state plasma levels. After application of the gel the skin was 55 
occluded with the patch and occlusive tape was applied to 
prevent evaporation of the formulation Blood samples were 
obtained for 7 days while the patch was changed with new 
formulation at 3.5 days. The blood samples were immedi-
ately centrifuged at 10,000xg for 3 min; plasma was sepa- 60 
rated and stored at 70 g C until analysis. 
Staining 
The patches were removed at predetermined time points 
and the site was cleaned with sterile gauze. Gentian violet/ 
India ink was applied as the dyeing agent at the MN treated 65 
sites and allowed to dry before excess dye was removed with 
ethanol and gauze. Both the dyes stain the viable epidermis 
INTRODUCTION 
Transdermal drug delivery is a potential alternative route 
for a host of drug molecules that are difficult to deliver via 
the oral or parenteral route. It avoids first pass effects, 
hepatotoxicity, gastric irritation issues as well as needlepho-
bia. However, only small, lipophilic molecules can be deliv-
ered by passive diffusion alone across the stratum comeum 
(SC), the main barrier to transdermal drug delivery (Praus-
nitz, et al. (2004), Prausnitz and Langer (2008)). Hence, 
physical and chemical enhancement techniques are being 
used to enhance the number the molecules that can be 
delivered via this route. Physical enhancement techniques 
include iontophoresis, electroporation, low frequency ultra-
sound and microneedle (MN) enhanced delivery. Chemical 
enhancement techniques include chemical enhancers and the 
prodrugs/codrugs approach. In this study MN enhanced 
delivery was combined with a codrug approach to develop 
a seven day sustained release patch system. MN is a mini-
mally invasive physical enhancement technique. The 
method adopted is the "poke and patch" approach3 where 
solid stainless steel MN arrays are used to create micropores 
(also referred to as micro channels) across the SC. The MN 
is then removed and a matrix/reservoir type patch is applied 
to deliver drugs through the micropores. Pain associated 
with the application of these MNs is also negligible when 
compared to a hypodermic needle (Kaushik, et al., (2001), 
Gill, et al. (2008)) which could potentially lead to better 
compliance, one of the major drawbacks of addiction 
therapy (O'Malley, et al. (1992)). 
Naltrexone (NTX), the model compound (M.W of341.41, 
log P of 1.8) is one of the leading FDA approved pharma-
cotherapy for alcohol addiction. It is a µ-opioid receptor 
antagonist and is known to decrease alcohol craving in 
recovering addicts. The drug exerts its mechanism of action 
by attenuating the ethanol induced stimulation of the 
mesolimbic-dopaminergic pathway (Lee, et al. (2005), Swift 
(2010)). Currently, NTX is marketed as a 50 mg once daily 
oral formulation, Revia® (Naltrexone Hydrochloride). This 
has compliance issues in addicts Hulse and Basso (2000), 
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Volpicelli (1997). It also has an oral bioavaibility ranging 
from 5-40% and is associated with side effects like hepato-
toxicity, nausea and vomiting (1996, PDR. 2d Ed, New 
Jersey, Medical Economics). The intramuscular injectable 
28 day controlled release formulation of NTX; Vivitrol™ 5 
was approved by the FDA in 2006. Injection site reactions 
and difficulty of removal in case of emergency opiate 
treatment in addition to the above are some of the major 
drawbacks of this dosage form (Alkermes, Vivitrol Alert). 
6-~ naltrexol is the major metabolite of NTX and has a 10 
higher half-life of 13 hours in plasma compared to that of 4 
hours for NTX. It has been shown to be an effective therapy 
for alcohol abuse as well (McCaul, et al., (2000)). 
NTX cannot be delivered in relevant therapeutic concen-
trations transdermally by passive delivery alone. Some of 15 
the earlier efforts in the laboratory have looked at delivery 
ofNTX via the prodrugs and codrugs approach. The results 
indicated that although flux enhancement was achieved in 
vitro in some cases, the flux enhancement was not enough to 
deliver the molecule in therapeutically relevant concentra- 20 
tions in vivo (Hammell, et al. (2004), Haranath, et al. (2005), 
Kiptoo, et al. (2008)). Using MN it has been shown both in 
vitro as well as in vivo that NTX can be delivered in the 
lower therapeutic range of 2 ng/ml Banks, et al. (2008), 
Wermeling, et al. (2008), Verebey, et al. (1976)). However, 25 
one of the issues with this approach is that the micropores 
begin to close between 48-72 hour (Wermeling, et al. (2008), 
Banks, et al. (2010), Kalluri and Banga (2011 ). Therefore, in 
order to develop a 7 day patch system, pore lifetime 
enhancement techniques need to be employed along with 30 
MN for successful therapy. 
Different techniques can be used to delay barrier recovery 
after MN treatment. The skin is a self-regulatory organ and 
employs different methods for recovery after assault. Cuta-
neous wound healing itself consists of multiple phases, 35 
inflammatory response being the first step. Increased syn-
thesis and secretion of lamellar body contents and transfor-
mation into bilayer is also a part of the recovery process 
(Feingold (2002), Feingold, et al. (2000), Menon, et al. 
(1992). Occlusion alone can also delay the recovery process 40 
by decreasing the water flux across the barrier, one of the 
major signals for recovery of structure and function 
(Grubauer et al. (1989)). 
There are several literature reports indicating the increase 
in expression of both COX-I and COX-2 following damage 45 
to the skin and the role of, both the enzymes in cutaneous 
repair (Pecker, et al. (2007), Davidson and Breyer (2003), 
Muller-Decker, et al. (2002), Futagami, et al. (2000)). 
Diclofenac (DIC) is a NSAID that nonselectively inhibits 
both COX-I and COX-2 thereby preventing formation of 50 
downstream products like prostaglandins and thromboxane, 
thus decreasing inflammation. It is currently available on the 
market as an oral as well as topical formulation and is the 
first choice ofNSAID for this project. Previous experiments 
showed that by daily application of Solaraze Gel® (3% 55 
diclofenac sodium, 2.5% hyaluronic acid) after one time 
application of MN was able to deliver NTX over the seven 
day time period in hairless guinea pig (HGP) (Banks, et al. 
(2011 ). Daily application is irrational for a patch system and 
co formulating the drugs in high concentration at a pH 60 
optimum of 5 (pH of the outer layer of the skin is 4.5-5.5)32 
is difficult because the drugs have different physicochemical 
properties (FIG. 11). This leads to the codrug approach. The 
3-0-ester-codrug contains a biolabile ester linkage that can 
be cleaved by hydrolytic enzymes like esterase as soon as it 65 
reaches the epidermal region of the skin to release the parent 
compounds (Vaddi, et al. (2009), Prusakiewicz, et al. (2006), 
60 
Oesch, et al. (2007). Once in the skin the DIC will act locally 
to keep the pores open while NTX is delivered systemically. 
The overall objective of this paper is to use a codrug 
approach to reduce the inflammatory response in combina-
tion with occlusion for delayed barrier recovery following 
MN treatment to reach the ultimate goal of a seven day patch 
system. 
Materials and Methods 
Chemicals 
Naltrexone HCl was purchased from Mallinckrodt (St. 
Louis, Mo.), diclofenac acid from AK Scientific, Inc. 
(Mountain view, CA) and diclofenac sodium salt from TCI 
America (Portland, Oreg.). Water was purified using 
NANOpure Diamond™, Barnstead water filtration system. 
Hanks' balanced salts modified powder, propylene glycol 
and ethanol, 200 proof were purchased from Sigma (St. 
Louis, Mo.). 4-(2-Hydroxyethyl)-1-piperazineethanesulfo-
nic acid (HEPES), sodium bicarbonate, sodium acetate, 
acetic acid and gentamicin sulfate and were obtained from 
Fis her Scientific (Fairlawn, N .J.). 1-0ctanesulfonate, 
sodium salt was obtained from Regis Technologies, Inc 
(Morton Grove, Ill.). Trifluroacetic acid (TFA), triethylam-
ine (TEA) and acetonitrile (ACN) were obtained from EMD 
chemicals (Gibbstown, N.J.). Natrosol® (hydroxyethlycel-
lulose) was obtained from Hercules. Chemicals for codrug 
synthesis were purchased from Alfa Aessar. 
Synthetic Procedure for Codrug 
Diclofenac sodium salt was dissolved in 1:1 (Ethyl 
acetate:Water) mixture and acidified with concentrated 
hydrochloric acid. Organic layer was separated and aqueous 
layer treated with ethyl acetate two times. Combined organic 
layer was dried on anhydrous sodium sulfate and rotary 
evaporated to remove reaction solvents. Diclofenac free acid 
was activated with DCC (N, N'-Dicyclohexyl carbodiim-
ide)) and DMAP (4-Dimethylaminopyridine) in anhydrous 
tetrahydrofuran. After two hours, equivalent naltrexone was 
added in dry tetrahydrofuran. Combined reactants were 
allowed to stir over night under nitrogen atmosphere. After 
completion of the reaction, solvents were removed under 
reduced pressure and reaction crude mixture purified by 
flash silica gel column chromatography eluting with 80% 
ethyl acetate and 20% cyclohexane and codrug-1 was 
obtained in 56% (Scheme-I) yield. The codrug-1 was dis-
solved in I, 4-dioxane and an equimolar amount of 2M 
hydrochloric acid in dioxane was added and refluxed for 1.5 
hrs, and precipitated with hexanes to get hydrochloride salt 
of codrug-24 (Scheme-I) 
1HNMR (CDC13 , 300 MHz): o 7.29 (m, 2H), 7.19 (t, lH), 
6.93 (m, 2H), 6.75 (d, lH), 6.60 (d, 2H), 6.57 (d, lH), 4.78 
(s, lH), 3.67 (s, 2H), 3.12 (m, 2H), 2.79 (m, lH), 2.32 (t, 
2H), 2.27 (m, 2H), 2.05 (m, 2H), 1.69 (m, 2H), 1.62, (m, 
2H), 0.46 (m, lH), 0.31 (m, 2H), 0.30 (m, 2H) 
13CNMR(CDC13 , (300 MHz): o 4.22, 4.41, 9.77, 23.31, 
31.09, 31.59, 36.45, 38.50, 43.75, 51.01, 59.48, 62.15, 
70.28, 90.93, 118.75, 119.52, 122.45, 123.05, 124.19, 
124.31, 128.30, 128.97, 129.73, 130.38, 130.64, 131.31, 
132.63, 138.09, 142.92, 147.77, 169.98, 207.67 
HRMS: Calculated for C34H320 5 N2 Cl2 618.1688 and 
found 618.1697. 
Hydrochloride Salt of Codrug-24 
1HNMR (CDC13 , 300 MHz): 09.98 (bs, NW) 7.33 (m, 
2H), 7.13 (t, 111), 6.99 (m, 3H), 6.61 (d, lH), 6.57 (d, lH), 
4.97 (s, lH), 4.73 (s, lH), 4.10 (s, 2H), 3.60 (m, 2H), 3.14 
(m, 4H), 2.92 (m, lH), 2.65 (m, 2H), 2.41 (d, lH), 1.82 (m, 
3H), 1.25 (m 2H), 0.84 (m, 4H), 0.62 (m, lH) 
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Quantitative Analysis 
NTX, DIC and the codrug concentrations in all samples 
were quantified using a HPLC assay which is a modified 
version of the previously reported NTX assay (Milewski and 
Stinchcomb (2011)). The HPLC system consisted of a 5 
Waters 717 plus auto sampler, a Waters 600 quaternary 
pump, and a Waters 2487 dual wavelength absorbance 
detector with Waters Empower™ software. A Perkin Elmer 
Spheri5 VL Cl8 column (5µ, 220x4.6 mm), a Cl8 guard 
column (15x3.2 mm) was used with the UV detector set at 10 
a wavelength of 280 nm. The mobile phase consisted of 
70:30 (v/v) ACN:(0.1% TFA with 0.065% I-octane sulfonic 
acid sodium salt, adjusted to pH 3.0 with TEA aqueous 
phase). Samples were run at a flow rate of 1.5 ml/min with 
a run time of 8.5 min. The injection volume used was 25 µl 15 
for receiver samples and I 00 µl for the skin samples. For the 
plasma samples the mobile phase consisted of 50:50 (v/v) 
ACN:(O.I % TFA with 0.065% I-octane sulfonic acid 
sodium salt, adjusted to pH 3.0 with TEA aqueous phase). 
Samples were run at a flow rate of 1.0 ml/min with a run 20 
time of 37 minutes and injection volume of 25 µ!. 
Chemical and Enzymatic Stability 
Chemical and enzymatic stability was determined for the 
codrugs. For chemical stability studies, the codrug was put 
in prewarmed 0.3M acetate buffer pH 5.0 after solubilization 25 
in <5% ACN, if required, at 32° C. in an incubator. Samples 
were withdrawn at regular intervals and injected into the 
HPLC after appropriate dilutions. Enzymatic stability stud-
ies are important for estimation of conversion of codrugs in 
the plasma. For plasma stability studies prewarmed HGP 30 
plasma at 37° C. was spiked with codrug solution and 
samples were withdrawn at regular intervals. 100 µl of 
plasma sample was extracted with I ml of I: I ACN:ethyl 
acetate, vortexed, centrifuged at I 0,000 rpm for 20 minutes 
on a bench top Eppendorf Mini Spin®. The supernatant was 35 
decanted into a glass tube and evaporated under nitrogen. 
Samples were reconstituted in I 00 µl ACN and injected onto 
the HPLC. All stability data was analyzed using pseudo first 
order kinetics. All stability studies were carried out at least, 
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stopper to prevent evaporation of formulation. Samples were 
collected at regular increments over 48 hours or for the 
length of the treatment. Drug was concentrated I 0 fold by 
evaporating I ml of the collected sample under nitrogen and 
reconstituting in I 00 µl of ACN for quantification. All 
samples were stored at 4 ° C. until analyzed by HPLC. The 
skin was removed at the end of the study and the treatment 
area was diced into small pieces using a scalpel after 
removing all excess drugs from top of the skin. Drug was 
extracted out by immersing the skin pieces in ACN over-
night in a shaker water bath at 32° C. Samples were injected 
into the HPLC after appropriate dilution for quantitative 
analysis. The donor was also removed and quantified at the 
end of the study by direct injection onto HPLC after suitable 
dilution using ACN. All data was analyzed using Fick's first 
law of diffusion. J ss =P* li.C where J ss is the steady state flux, 
P is the permeability coefficient and li.C is the concentration 
difference between the donor and the receiver. Since the 
receiver is maintained at sink conditions li.C is essentially 
the concentration of the donor. Steady state flux is obtained 
from a plot of cumulative amounts permeated per time. 
Permeability coefficients can be calculated using the known 
donor concentration. 
In Vivo Studies 
Fabrication of Transdermal Patches 
The transdermal patches were fabricated by sandwiching 
a blend of nitrile rubber and polyvinyl chloride plastic ring 
barrier to create a reservoir between the skin and the 
impermeable backing membrane (Scotchpak™ #1109 
SPAK 1.34 MIL Heat Sealable Polyester Film) and an 
ARcare® 7396 adhesive around the edge of the rubber 
spacer. 3MTM double sided tape was used on either side of 
the rubber to attach the backing on one side and to maintain 
contact with the skin on the other side and prevent evapo-
ration of the formulation. 
Dose Preparation and Application 
All animal experiments were approved by the University 
of Kentucky IA CUC. A proof of concept in vivo experiment 
was carried out. 4% w/w gels were prepared with the 
in triplicate. 
In Vitro Diffusion Studies 
The in vitro permeation experiments were carried out to 
determine the transdermal flux of the parent drugs and the 
codrug, permeation coefficients as well as the concentration 
40 hydrochloride salt form of the codrug. Gels were formulated 
by dissolving 4% codrug salt in PG: buffer at pH 5.0=10:90 
and 3.0% hydroxyethylcellulose (HEC) polymer (required 
to have a gel formulation). Polymer was dissolved over a 30 
minute period to obtain a homogenous gel. The solution was 
of the drug molecules in the skin at the end of the study. For 45 stirred until a viscous gel resulted and then left at room 
temperature for I 1h to 2 hours to remove bubbles and ensure 
complete polymerization. The gel was saturated with excess 
solid and therefore was cloudy. MN treated animals were 
first cleaned topically with isopropyl alcohol, and 50 MN 
all in vitro experiments Yucatan miniature pig (YP) skin was 
used. Full thickness skin was obtained by removing the 
subcutaneous fatty tissue by scalpel dissection, and stored at 
-20° C. A PermeGear flow-through (In-Line, Riegelsville, 
Pa., USA) diffusion cell system was used for the skin 
permeation studies. Skin for MN treatment was placed on a 
wafer of polydimethylsiloxane polymer, which mimics the 
underlying mechanical support of tissue because of its 
comparable structural flexibility and elasticity. The skin was 
pierced 20 times with a 5 MN array (making 100 individual 
and non-over lapping piercings) before mounting the skin in 
the diffusion cell. MN pores were distributed evenly within 
the 0.95 cm2 area of skin. Untreated skin samples were 
mounted directly onto the diffusion cells. The setup was 
maintained at 32° C. using a circulating water bath. Data 60 
collected using a minimum of 3-4 cells per treatment group. 
The receiver solution was water alkalified to pH 7.4 con-
taining 20% ethanol at 37° C. Gentamycin sulfate (50 mg/L) 
was added to the receiver for 7 day studies as an antibacterial 
agent. The receiver flow rate was adjusted to 1.5 ml/h to 65 
maintain skin conditions. Each cell was charged with 0.25 
ml of the donor and the diffusion cells were covered with a 
50 array was applied twice mutually perpendicular to each 
other to give a total of 100 pores at each site. 0.3 mL gel 
doses were applied to the dorsal region of the HGP. After 
application of the gel the skin was occluded with the 
occlusive patch and biocclusive tape was applied to prevent 
55 evaporation of the formulation. The patch was changed with 
new formulation at 3.5 days such that more than 50% intact 
codrug was always present in formulation. A control experi-
ment was also carried out to look at the effect of NTX HCl 
alone in the same vehicle on pore closure kinetics. A 9% 
solution ofNTX HCl was used to prepare a 3% HEC gel and 
all other methods of application were constant with the 
codrug gel. The patches were removed to obtain data at 
successive 24 h time intervals. 
Staining 
The patches were removed at predetermined time points 
and the site was cleaned with sterile gauze. Gentian violet/ 
India ink was applied as the dyeing agent at the MN treated 
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produce therapeutic efficacy. As also noted from the flux and 
skin concentration data, significantly higher amounts of 
naltrexone was found in the receiver while diclofenac was 
retained in the skin in higher concentration at 48 h. This 
sites and allowed to dry before excess dye was removed with 
ethanol and gauze. Both the dyes stain the viable epidermis 
but not the intact SC. Hence, a grid is observed only in the 
presence of micropores in the skin, no staining is observed 
in its absence. 
Statistical Analysis 
Data for all experiments are reported as mean±standard 
deviation. Statistical analysis of data will be carried out with 
Students' t-test and one way ANOVA with post hoc Tukey's 
pairwise tests, ifrequired, using SIGMA-STAT (SPSS, Inc., 
Chicago, Ill., USA) software. P<0.05 will be considered to 
be statistically significant. 
5 difference in flux and skin concentration could be attributed 
to the difference in physicochemical properties of the drug 
molecules. While naltrexone is positively charged at the skin 
surface pH of 5 (ref), at least 90% of the diclofenac will be 
negatively charged. Since skin is known to possess a nega-
Results and Discussion 
Synthesis. The codrug and it's hydrochloride salt were 
synthesized successfully. The structures were verified. 
10 tive charge due to presence of negatively charged carboxylic 
acid groups this might lead to slower migration and higher 
retention of diclofenac molecules in the skin. Since the 
hypothesis behind the project is based on the fact that 
diclofenac would work locally to reduce subclinical inflam-
15 matory response thus enhancing the drug delivery window, 
this characteristic of the molecules would be beneficial in 
the long term. 
HPLC method development. HPLC assay development 
for the parent drugs and the codrug was the first step towards 
quantification of the data. The retention time of NTX was 
2.3 minutes, DIC was 3.5 minutes and codrug was 6.5 
minutes. The retention time for the same compounds in 
plasma samples were 3.3 minutes, 16 minutes and 33 
minutes. All retention times reported are value±0.1 minutes. 
Samples were analyzed within a linear range of standard 
curve for all the three compounds from 100-10000 ng/ml. 
The standard solutions exhibited excellent linearity over the 25 
entire concentration range employed in the assays. 
From literature it is known that a charged species has 
higher flux through MN treated skin compared to a non-
20 treated control. This property is attributed to the enhanced 
solubility of a charged species in an aqueous donor rather 
than the molecular species itself (Banks, et al. (2008). 
Viscosity of the donor formulation also has a predominant 
effect on the flux across MN treated skin where it has been 
Stability studies. The chemical and enzymatic stability 
data indicated that the chemical half-life of the codrug in the 
pH 5.0 buffer was 3.9±0.56 days and the enzymatic half-life 
in the HGP plasma was 6.4±0.84 minutes. In both the studies 30 
regeneration of the parents were observed with the degra-
dation of the codrug. The chemical stability indicates that 
the codrug is not stable enough in an aqueous formulation 
for the development of a 7-day transdermal drug delivery 
system. But still it could be utilized as a learning tool for 35 
understanding the bioconversion of the codrug in the epi-
dermal region of the skin as well as for proof of concept that 
the codrug methodology could work to enhance the drug 
delivery window following one time application of the MN. 
The plasma stability study indicates that even if intact 40 
codrug permeates the skin and reaches the systemic circu-
lation it would cleave back to the parent drugs almost 
immediately thus contributing to the naltrexone flux. The 
systemic concentration of diclofenac should not be of con-
cern since it would be orders of magnitude lower compared 45 
to therapeutically relevant systemic doses. 
In vitro experiments. The goal of the first set of in vitro 
experiments was to estimate flux and skin concentration of 
the base form of the codrug. A saturated donor solution was 
used consisting of propylene glycol (PG):ethanol: water=43: 50 
43:14 and had a concentration of 4.5 mg/ml. 4 treatment 
groups each having 3 diffusion cells (MN treatment) were 
dosed and then cells were removed every 12 hours to obtain 
the skin concentration of the parent drugs as well as the 
codrug at different timepoints. An intact skin control was 55 
also present for the entire length of the study (48 hours). 
Steady state flux was obtained both from NTX and DIC of 
0.42±0.12 nmol/(cm2/h) and 0.1910.06 nmol/(cm2/h) 
respectively (FIG. 14A). The flux ofNTX was significantly 
higher compared to the flux of DIC (p<0.05). The skin 60 
concentration data shows that the codrug degraded in the 
skin to regenerate back the parent drugs even at 24 hours and 
amount of parent drugs from the codrug increased with time. 
shown that 17 fold flux enhancement was obtained using a 
low viscosity, aqueous donor compared to a high viscosity 
propylene glycol (PG) rich donor (concentration was main-
tained at 110 mg/ml). No significant difference in flux was 
observed across untreated intact skin using the above 
donors. Hence the hydrochloride salt form of the codrug was 
tested for higher solubility and flux in aqueous donor for 
subsequent experiments. 
In the next set of experiment hydrochloride salt of codrug 
(FIG. 12) was used as the donor solution with a concentra-
tion of39.3 mg/ml in 0.3M acetate buffer at pH 5.0. The flux 
of NTX from the codrug salt was 5.42±1.5 nmol/(cm2/h) 
(FIG. 16) and the skin concentration for both NTX and the 
codrug increased (data not shown). Therefore a 13 fold flux 
enhancement was obtained by using the salt form over the 
free base form (p<0.005) which can be attributed to the 
solubility enhancement of the salt form in an aqueous donor. 
Precipitation issues were observed with purely aqueous 
donor, so in vitro formulation development experiment was 
carried out by varying the amount of PG in the donor. 10%, 
25% and 50% PG was used with the salt form and it was 
observed that while there was no significant difference in 
flux between the aqueous formulation and 10% PG contain-
ing formulation (p<0.05), but flux decreased significantly 
for higher concentrations of PG. All experiments were 
carried out with saturated donor solution. The data was 
compared using one way ANOVA and Tukey's posthoc 
analysis for pair wise multiple comparisons. The 10% PG 
containing formulation was hence chosen for in vivo studies. 
In vivo studies. The pores can be clearly visualized with 
gentian violet in FIG. 17 (A) immediately following MN 
treatment. In panel (B) the pores cannot be visualized at day 
4 (96 h) pores treatment with MN followed by application of 
NTX HCl gel under occlusion. This is in agreement with 
previously reported data in pharmacokinetic studies where it 
has been shown that the micropores close anywhere between 
a 48-72 h timeline following MN treatment under occlusion 
(Stan PNAS ref). Pores can be visualized by India iuk 
staining in panel C where the hydrochloride salt form of the 
codrug was used following MN treatment indicating that the It also showed that the DIC increased in the skin with time 
and was higher compared to the NTX at 48 hours. 
The codrug cleaved, and NTX flux was obtained from the 
base form of the codrug, although it was not high enough to 
65 pores can stay open up to a 7 day time point. Therefore, it 
can be concluded from the studies that the codrug is effective 
in keeping the pores open analogous to our hypothesis. 
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From the studies so far it can be concluded that the codrug 
cleaved back to parent drugs both in stability studies as well 
as in vitro studies. The salt form of the codrug improved 
solubility and flux significantly in in vitro studies. Subse-
quent in vivo studies with the salt form in an optimized 10% 5 
PG containing formulation kept the pores open for a 7 day 
target drug delivery window but the flux of NTX from the 
codrug was not high enough to quantify in an hairless guinea 
pig model. This could be predicted from clearance estima-
tion from previous pharmacokinetic studies with NTX in the 10 
same animal model based on size of treated area since 
Jss* A~Css*Cl 
In this case with 4 patches A is 400 MN treatments, flux 15 
is 5.5 nmol/cm2/h and Cl is 5.6 L/h which leads to a Css of 
around 1 ng/ml, the LLOQ on the LCMS assay. Hence 
reliable pharmacokinetic data could not be obtained from 
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a second moiety derived from a cyclooxygenase (COX) 
enzyme inhibitor; 
wherein said first moiety is liuked to said second moiety 
to form a single chemical entity; 
wherein the compound has a structure selected from the 
group consisting of: 
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2. The compound of claim 1, wherein the opioid and the 
COX enzyme inhibitor are linked by a linker moiety. 
3. The compound of claim 2, wherein the linker moiety is 
cleavable. 
4. The compound of claim 3, wherein the linker moiety is 
cleavable by hydrolysis and/or enzymatic digestion. 
5. The compound of claim 2, wherein the linker moiety 
confers increased aqueous solubility to the compound. 
6. A method for treating a subject, comprising 
identifying a subject in need of treatment for a condition 
selected from the group consisting of narcotic depen-
dence, alcohol dependence, amphetamine dependence, 
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and smoking dependence; and delivering to the subject 
a therapeutically effective amount of the compound of 
claim 1. 
7. The method of claim 6, wherein following delivery to 
the subject, the compound is transformed into at least two 5 
active drug molecules. 
8. The method of claim 7, wherein the transformation is 
by hydrolysis and/or enzymatic digestion. 
9. The method of claim 6, wherein the compound is 
delivered transdermally. 10 
10. The method of claim 9, wherein compound achieves 
improved duration of microporation-assisted delivery of the 
opioid as compared to the parent. 
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